<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005849</article-id><article-id pub-id-type="pmc">PMC11860318</article-id><article-id pub-id-type="doi">10.3390/vetsci12020089</article-id><article-id pub-id-type="publisher-id">vetsci-12-00089</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A New Rapid Indirect ELISA Test for Serological Diagnosis of Feline Immunodeficiency</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ferrero</surname><given-names>Irene</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vetsci-12-00089" ref-type="aff">1</xref><xref rid="c1-vetsci-12-00089" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Poletti</surname><given-names>Paolo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vetsci-12-00089" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Giachino</surname><given-names>Enrica</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vetsci-12-00089" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8849-2051</contrib-id><name><surname>Filipe</surname><given-names>Joel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-vetsci-12-00089" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8542-9476</contrib-id><name><surname>Dall&#x02019;Ara</surname><given-names>Paola</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-vetsci-12-00089" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>He</surname><given-names>Xijun</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00089"><label>1</label>Agrolabo S.p.A., 10100 Scarmagno, Italy</aff><aff id="af2-vetsci-12-00089"><label>2</label>Department of Veterinary Medicine and Animal Sciences, University of Milan, 26900 Lodi, Italy</aff><author-notes><corresp id="c1-vetsci-12-00089"><label>*</label>Correspondence: <email>irene.ferrero@agrolabo.it</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>89</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>The aim of this work was the development of a new rapid indirect Enzyme-Linked Immunosorbent Assay (ELISA) assay, called FIVCHECK Ab ELISA, for the detection of antibodies against Feline Immunodeficiency Virus (FIV) in feline serum/plasma samples. FIV is a virus belonging to the Retroviridae family that affects feline immune cells, causing a progressive immunosuppression similar to the acquired immune deficiency syndrome (AIDS) in humans caused by human immunodeficiency virus (HIV). Diagnosis is usually performed by clinicians using rapid ELISA or lateral flow tests that detect FIV antibodies. The new test is the result of an extensive set-up phase carried out by the Research and Development (R&#x00026;D) team of Agrolabo S.p.A., considering different concentrations of samples and reagents. In addition, the test cut-off was assessed and confirmed through several methods, including the Youden&#x02019;s index and ROC curve, to achieve the best possible test performance in terms of sensitivity, specificity, accuracy, reliability, and repeatability of results. This study demonstrates that the FIVCHECK Ab ELISA has high sensitivity and specificity, making it also suitable for the analysis of highly lipemic or hemolytic samples, as no interferences were observed on the tested samples. In fact, FIVCHECK Ab ELISA was validated against the ELISA rapid test SNAP FIV/FeLV Combo (IDEXX) considered as reference: it agreed at 100%, with 100% sensitivity (95% confidence interval (CI): 88.5&#x02013;100%) and 100% specificity (95% CI: 94.0&#x02013;100%). Moreover, the performance of the new ELISA was compared with two other rapid indirect ELISAs widely used in veterinary practice, INgezim FIV (Gold Standard Diagnostics) and VetLine FIV (NovaTec). The FIVCHECK Ab ELISA agreed at 100% with INgezim FIV and 92.2% with VetLine FIV. Moreover, the new FIVCHECK Ab ELISA is an accurate and precise test with coefficients of variation lower than 10% both in intra- and inter-assays. The new test is fast as it provides correct and reliable results very quickly (25 min), without the need of particular laboratory equipment such as thermostats, because all incubations are performed at room temperature. Only the interpretation of results is performed instrumentally, by reading the OD values at 450 nm using an ELISA microplate reader (Multiskan SkyHigh, Thermo Fisher Scientific, Waltham, MA, USA). The new assay contains ready-to-use and safe reagents for the end-user and has a long-term storage up to 18 months at +2&#x02013;8 &#x000b0;C. All these features make this test optimal for use in veterinary clinics and practices.</p></abstract><abstract><title>Abstract</title><p>The Feline Immunodeficiency Virus (FIV) is a lentivirus belonging to Retroviridae family that affects feline immune cells, causing a progressive immunosuppression by depleting CD4+ T-lymphocytes, similarly to the acquired immune deficiency syndrome (AIDS) in humans caused by human immunodeficiency virus (HIV). Diagnosis is usually performed by clinicians using rapid Enzyme-Linked Immunosorbent Assay (ELISA) or lateral flow tests that detect FIV antibodies. The aim of this work was the development of FIVCHECK Ab ELISA, a new rapid indirect assay for the detection of FIV antibodies in feline serum/plasma samples; FIVCHECK Ab ELISA was developed after a meticulous set-up and cut-off analysis through several methods, including the Youden&#x02019;s index and ROC curve, to achieve the best test performance. The new kit was validated by testing 115 feline sera (38 positives and 77 negatives for FIV antibodies) against the ELISA rapid test SNAP FIV/FeLV Combo (IDEXX). Moreover, 103 sera (28 positives and 75 negatives) were also analyzed with two other rapid indirect ELISAss, INgezim FIV (Gold Standard Diagnostics) and VetLine FIV (NovaTec); FIVCHECK Ab ELISA agreed at 100% with SNAP (100% sensitivity, 95% confidence interval (CI): 88.5&#x02013;100%; 100% specificity, 95% CI: 94.0&#x02013;100%), 100% with INgezim FIV and 92.2% with VetLine FIV. Intra- and inter-assay accuracy and precision gave coefficients of variation lower than 10%. The new ELISA is a simple and quick test that provides reliable results for veterinary clinics and practices.</p></abstract><kwd-group><kwd>FIV</kwd><kwd>immunodeficiency</kwd><kwd>FIVCHECK Ab ELISA</kwd><kwd>gp40</kwd><kwd>ELISA</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00089"><title>1. Introduction</title><p>The Feline Immunodeficiency Virus (FIV) is an enveloped single-stranded RNA lentivirus that belongs to the Retroviridae family isolated in cats [<xref rid="B1-vetsci-12-00089" ref-type="bibr">1</xref>]. FIV has many similarities to human immunodeficiency virus (HIV) and causes an AIDS-like syndrome in the domestic cat. FIV infects T-lymphocytes, cells of monocyte/macrophages/microglia lineage, and cells of the central nervous system. The viral replication is initiated by the interaction of the viral glycoproteins with CD134, up-regulated on activated CD4+ T cells, which permits the virus entry into the host cell cytoplasm [<xref rid="B2-vetsci-12-00089" ref-type="bibr">2</xref>]. FIV integrates its viral retrotranscribed RNA into DNA in the cat&#x02019;s genome.</p><p>The integrated provirus is bordered by long terminal repeats (LTRs) and possesses <italic toggle="yes">gag</italic>, <italic toggle="yes">pol</italic>, and <italic toggle="yes">env</italic> genes, common elements of all retroviruses, and several genes that code for small accessory proteins such as Vif and Rev. The <italic toggle="yes">gag</italic> gene codes for a myristoylated matrix p15 protein, a capsid p24, and a nucleocapsid p13 proteins. FIV <italic toggle="yes">pol</italic> codes for the protease, reverse transcriptase, integrase, and deoxyuridine triphosphatase. The <italic toggle="yes">env</italic> gene codes for the heavily glycosylated surface unit protein gp95 and the transmembrane protein gp40 [<xref rid="B2-vetsci-12-00089" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-12-00089" ref-type="bibr">3</xref>]. Three phases of FIV infection are recognized: primary (acute), subclinical, and clinical. In the first phase, the animal is viremic, and a sharp decline in lymphocyte populations, particularly CD4+ (helper) T-lymphocytes, occurs. In the second and longest phase, cats enter a long subclinical phase that can last for many years; in this case, the level of circulating free virus is suppressed, viral replication is very limited, the production of FIV antibodies is persistently high and the animal is clinically healthy. The levels of CD8+ T-lymphocytes (cytotoxic) increase, which, combined with the dropping level of CD4+ T-lymphocytes, produce an inversion of the CD4+/CD8+ ratio that may persist for life. However, both CD4+ and CD8+ T-lymphocyte numbers gradually decline, causing progressive dysfunction of the immune system until cats enter the third and clinical phase, during which viral replication increases and clinical disease becomes apparent [<xref rid="B2-vetsci-12-00089" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-12-00089" ref-type="bibr">3</xref>,<xref rid="B4-vetsci-12-00089" ref-type="bibr">4</xref>,<xref rid="B5-vetsci-12-00089" ref-type="bibr">5</xref>]. Since FIV causes immunodeficiency syndrome by depleting CD4+ T-lymphocytes, the risk of opportunistic infections, neurological diseases, and cancer in cats increases [<xref rid="B5-vetsci-12-00089" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-12-00089" ref-type="bibr">6</xref>]. In most infected cats, however, FIV itself does not cause severe clinical signs, and FIV-infected cats may live many years without any health problems [<xref rid="B7-vetsci-12-00089" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-12-00089" ref-type="bibr">8</xref>].</p><p>Like HIV, FIV transmission occurs mainly through bite or vertically during pregnancy, but also via mucosal exposure and blood transfer [<xref rid="B5-vetsci-12-00089" ref-type="bibr">5</xref>,<xref rid="B7-vetsci-12-00089" ref-type="bibr">7</xref>]. Since infected cats usually develop high concentrations of FIV-specific antibodies and FIV produces a persistent infection from which cats do not recover, detection of antibodies is indicative of FIV infection. Thus, diagnosis is usually performed by using rapid ELISA or lateral flow immunoassays that detect FIV antibodies. Other assays such as immunofluorescent assay (IFA), Polymerase chain reaction (PCR) or Western blot may be used as confirmatory testing [<xref rid="B1-vetsci-12-00089" ref-type="bibr">1</xref>,<xref rid="B4-vetsci-12-00089" ref-type="bibr">4</xref>,<xref rid="B9-vetsci-12-00089" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-12-00089" ref-type="bibr">10</xref>]. The purpose of this work is the development of FIVCHECK Ab ELISA, a new rapid indirect assay for the detection of FIV antibodies in feline serum/plasma samples.</p></sec><sec id="sec2-vetsci-12-00089"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00089"><title>2.1. Samples Collection</title><p>In order to both set up the new ELISA technique and assess its reliability, a total of 115 sera/plasma samples from cats with various clinical conditions were collected from 4 veterinary clinics in northern and central Italy. All samples used in this study were first tested with other assays and thus classified as positive or negative for FIV antibodies. Some of these samples were highly lipemic or hemolytic. No information was provided about breed, sex, age, clinical outcomes, disease progression, or treatments of patients with drugs, thus no sample selection was performed to contemplate the broadest possible cases.</p></sec><sec id="sec2dot2-vetsci-12-00089"><title>2.2. ELISA Plate Preparation</title><p>Nunc PolySorp and Costar High Binding microplates (Thermo Fisher Scientific, Waltham, MA, USA) were used in the set-up of the test. All coating and blocking conditions used in the development of the new indirect ELISA test are described in standardized protocols [<xref rid="B11-vetsci-12-00089" ref-type="bibr">11</xref>,<xref rid="B12-vetsci-12-00089" ref-type="bibr">12</xref>,<xref rid="B13-vetsci-12-00089" ref-type="bibr">13</xref>] and based on internal company protocols and experience. In the preliminary phases, Nunc and Costar microplates were coated with the recombinant antigen derived from the envelope transmembrane glycoprotein gp40 of FIV at concentrations of 0.25, 0.5, 1, and 2 &#x003bc;g/mL in coating buffer formed by carbonate-bicarbonate (CB) buffer pH 9.6 and incubated at +2&#x02013;8 &#x000b0;C, overnight (O/N). Successively, after a washing step with Wash buffer (Agrolabo S.p.A., Scarmagno, Italy), plates were blocked with two commercial Blocking buffers (Surmodics, Eden Prairie, MN, USA), for 1 h at room temperature (RT). The Blocking Buffer 1 has pH 7.0&#x02013;7.4, contains bovine protein in phosphate-buffered saline (PBS) but not preservatives. Instead, the Blocking Buffer 2 has pH 6.5&#x02013;7.5 and contains bovine protein and preservatives (0.02% methylisothiazolone and 0.02% bromonitrodioxane). The plates were then drained, left to dry, and stored at +2&#x02013;8 &#x000b0;C.</p></sec><sec id="sec2dot3-vetsci-12-00089"><title>2.3. FIVCHECK Ab ELISA</title><p>The new test is the result of an extensive set-up phase carried out by the Research and Development (R&#x00026;D) team of Agrolabo S.p.A., considering different concentrations of antigen, conjugate, controls, and sample dilutions, to achieve the possible best test performance in terms of sensitivity, specificity, accuracy, reliability, and repeatability of results.</p><p>Nunc PolySorp microplates were prepared as previously described with 0.5 &#x003bc;g/mL of FIV recombinant antigen and Blocking Buffer 2. In FIVCHECK Ab ELISA, two types of positive controls (PCs) consisting of anti-histidine (His) tag antibodies labeled with horseradish peroxidase (HRP), PC1 (Abcam Limited, Cambridge, UK) and PC2 (Sigma-Aldrich, St. Louis, MO, USA), the negative control (NC), and samples, diluted 1:200 in sample diluent formed by PBS and bovine serum albumin (BSA) (Agrolabo S.p.A., Scarmagno, Italy), were distributed 100 &#x000b5;L in each well and incubated 10 min at RT. During this incubation, if the sample being tested contained specific anti-FIV antibodies (positive sample), they bound to the antigen attached to the wells, forming the antigen&#x02013;antibody complex. After a washing step with Wash buffer in order to eliminate all the unbound material, 100 &#x000b5;L/well of the anti-Cat IgG conjugate antibody labeled with HRP (Abcam Limited, Cambridge, UK) was added and incubated for 10 min at RT. After a second round of washes, 100 &#x000b5;L of the substrate/chromogen 3,3&#x02032;,5,5&#x02032;-Tetramethylbenzidine (TMB) (Surmodics, Eden Prairie, MN, USA) was added and incubated for 5 min at RT in the dark, developing a colorimetric reaction (blue color was index of positive samples, no color of negative ones). Then, the reaction was stopped by adding 100 &#x000b5;L of Stop solution formed by sulphuric acid 0.2 M (Agrolabo S.p.A., Scarmagno, Italy), and the blue reaction turned into shades of yellow. The interpretation of results was performed by reading the optical density (OD) values at 450 nm using an ELISA microplate reader. The test was considered valid if positive control had an OD value above 0.6 and the negative control below 0.1.</p><p>The positivity or negativity of each sample was evaluated by calculating the &#x0201c;negative cut-off&#x0201d; using Equation (1) and &#x0201c;positive cut-off&#x0201d; using Equation (2) based on the OD value of the negative control:<disp-formula>Negative cut-off = OD negative control + 0.20<label>(1)</label></disp-formula><disp-formula>Positive cut-off = OD negative control + 0.28<label>(2)</label></disp-formula></p><p>The sample was considered negative if the OD value was lower than negative cut-off, positive if the OD value was greater than the positive cut-off, and doubtful if the OD value was between the two cut-offs.</p></sec><sec id="sec2dot4-vetsci-12-00089"><title>2.4. FIVCHECK Ab ELISA Validation</title><p>The R&#x00026;D team of Agrolabo S.p.A validated the FIVCHECK Ab ELISA by testing 115 feline sera (38 positives and 77 negatives) against the ELISA rapid test SNAP FIV/FeLV Combo (IDEXX) considered as reference. The number of samples tested was in line with that used in other bibliographic studies for validation of ELISA tests [<xref rid="B14-vetsci-12-00089" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00089" ref-type="bibr">15</xref>,<xref rid="B16-vetsci-12-00089" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-12-00089" ref-type="bibr">17</xref>].</p><p>Briefly, in the SNAP FIV/FeLV Combo (IDEXX), 3 drops of sample were dispensed into a sample tube by using the pipette provided in the kit, then 4 drops of conjugate were added. After mixing the tube, the entire content of the sample was added carefully to the device well. The sample flowed across the result window, reaching the activation circle in a short time. When color appeared in the device activation circle, this signified that the activator had been pressed. Test results were read 10 min from the time of activation.</p></sec><sec id="sec2dot5-vetsci-12-00089"><title>2.5. Comparative Study</title><p>A comparative study was performed by analyzing 103 sera/plasma samples (28 positives and 75 negatives) with two other rapid indirect ELISA tests widely used in veterinary practice, the INgezim FIV ELISA (Gold Standard Diagnostics, Davis, CA, USA (<uri xlink:href="https://www.gsdx.us/">https://www.gsdx.us/</uri> accessed on 9 January 2025) and VetLine FIV ELISA (NovaTec, Baltimore, MD, USA).</p><p>In the INgezim FIV ELISA (Gold Standard Diagnostics), samples diluted 1:100 and controls were added to the plate (100 &#x003bc;L/well) and incubated at RT for 10 min. The plate was subsequently washed and 100 &#x003bc;L of conjugate diluted 1:100 was added into each microwell and incubated for 10 min. Then, after another washing step, 100 &#x003bc;L/well of TMB substrate was added. The plate was incubated at RT for 5 min, and, finally, the reaction was stopped by adding 100 &#x003bc;L of stop solution to each well. Results were assessed by reading the absorbance values with a microplate reader at a wavelength of 450 nm.</p><p>In the VetLine FIV ELISA (NovaTec), a volume of 100 &#x003bc;L of controls and diluted samples (1:100) was added into each well, except for one well that was left empty and used for the Substrate Blank. Then, the plate was incubated for 1 h at +37 &#x000b0;C and, after a washing step, 100 &#x003bc;L of conjugate was added into all wells except for the Substrate Blank well. The plate was newly incubated for 30 min at RT. After a second round of washes, 100 &#x003bc;L/well of TMB substrate was added and incubated for 15 min at RT in the dark. Finally, the reaction was stopped by adding 100 &#x003bc;L/well of stop solution. Results were assessed by reading the absorbance values with a microplate reader at a wavelength of 450 nm.</p></sec><sec id="sec2dot6-vetsci-12-00089"><title>2.6. Reproducibility</title><p>The ELISA&#x02019;s overall precision was evaluated by performing tests at different times in the same day and on different days under similar conditions, as mentioned in the guidelines [<xref rid="B18-vetsci-12-00089" ref-type="bibr">18</xref>]. In our case, the tests were carried out twice a day (morning and afternoon, to consider any changes in ambient temperature, although the ambient temperature in the laboratory was always kept between +20&#x02013;25 &#x000b0;C) for 14 or 15 consecutive days. Samples were repeated in duplicate for a total of 56 or 60 repetitions for each sample. All assays were conducted by two operators of the R&#x00026;D team of Agrolabo S.p.A to consider operator-related variables in different analytical sessions. The test&#x02019;s overall precision was defined for each sample through the evaluation of variation between wells within a single run of a plate (intra-assay) or between runs (inter-assay) by calculating the mean OD, standard deviation (SD) and minimum (Min), maximum (Max), and coefficient of variation (%CV) as the ratio between the SD and the mean OD value.</p></sec><sec id="sec2dot7-vetsci-12-00089"><title>2.7. Stability Studies</title><p>The R&#x00026;D team of Agrolabo S.p.A performed all real-time and accelerated stability studies. A single batch of ELISA plates was produced for the stability tests. Along with the plates, all reagents, such as positive/negative controls and conjugate, were prepared and then divided for the real-time stability and accelerated stability studies, to avoid the possibility of the mistaken results related to different batches&#x02019; production. In the real-time stability study, the Agrolabo&#x02019;s ELISA kit was stored at +2&#x02013;8 &#x000b0;C, in the accelerated one, it was stored at +37 &#x000b0;C to evaluate the aging process of the product by exposing it to elevated temperatures for a shorter time.</p><p>In the absence of specific regulations for stability testing on kits for veterinary use, the Standard Guide for Accelerated Aging of Sterile Medical Device Packages ASTM F1980-21 [<xref rid="B19-vetsci-12-00089" ref-type="bibr">19</xref>], which uses the Arrhenius equation to estimate the degradation of the medical device under accelerated conditions and represents an equivalent real-time shelf-life duration, was applied in this study. In this way, the &#x0201c;Accelerated Aging Time&#x0201d; (AAT), represented by the number of days during which the product is to be tested at the temperature in accelerated condition, was calculated through Formula (3):
<disp-formula id="FD100-vetsci-12-00089"><label>(3)</label><mml:math id="mm100" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>Accelerated</mml:mi><mml:mi>Aging</mml:mi><mml:mi>Time</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>AAT</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>Desired</mml:mi><mml:mi>Real</mml:mi><mml:mi>Time</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>RT</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msup><mml:msub><mml:mi mathvariant="normal">Q</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mrow><mml:mo>&#x000a0;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mi>AA</mml:mi></mml:msub><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mi>RT</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mn>10</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#x0201c;RT&#x0201d; is the desired time at which the product is to be stored, the Accelerated Aging Temperature (T<sub>AA</sub>) is the test temperature in accelerated condition, the real-time temperature (T<sub>RT</sub>) is the temperature at which the product is to be stored, and the aging factor (Q<sub>10</sub>) is a measure of how quickly a material system changes when the temperature is increased by +10 &#x000b0;C. It is typically between 1.8 and 2.5, with a value of 2.0 being the most common value.</p><p>In our case, ELISA tests will be stored at +2&#x02013;8 &#x000b0;C for 18 months. The time for accelerated stability study was calculated through the use of calculators found on the web [<xref rid="B20-vetsci-12-00089" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-12-00089" ref-type="bibr">21</xref>] based on the Arrhenius equation reported in ASTM F1980-21, and it corresponded to 6 weeks at +37 &#x000b0;C. Therefore, it can be concluded that 1 week at +37 &#x000b0;C is equivalent to 3 months at +2&#x02013;8 &#x000b0;C. In both real-time and accelerated stabilities, the first test was performed at the beginning of the study, at time zero (T<sub>0</sub>). Assays were repeated weekly for the first 6 weeks (T<sub>1</sub>&#x02013;T<sub>6</sub>), testing controls and positive/negative samples with reagents stored at +2&#x02013;8 &#x000b0;C and at +37 &#x000b0;C. Then, only plates at +2&#x02013;8 &#x000b0;C were tested for real-time stability every 3 months for up to 18 months (T<sub>7</sub>&#x02013;T<sub>12</sub>). In each analytical session and for each sample, the percentage remaining activity (%RA) or recovery was calculated, expressed as the ratio of the obtained OD value to that of time T<sub>0</sub>; the lower limit of acceptability was imposed at 70% [<xref rid="B22-vetsci-12-00089" ref-type="bibr">22</xref>]. The number of samples analyzed was in line with that used in other stability studies [<xref rid="B15-vetsci-12-00089" ref-type="bibr">15</xref>,<xref rid="B17-vetsci-12-00089" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot8-vetsci-12-00089"><title>2.8. Cut-Off Determination</title><p>The cut-off analysis was based on data obtained in ELISA validation. The ELISA cut-off was determined by comparison of several methods. Initially, the cut-off was calculated as the mean OD value of negative samples plus 3 times the standard deviation (SD) [<xref rid="B23-vetsci-12-00089" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-12-00089" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00089" ref-type="bibr">25</xref>], considering positive samples with OD above 10% the cut-off, negative with OD below 10% cut-off, and doubtful with OD between cut-off &#x000b1;10%, as reported in other commercial ELISAs [<xref rid="B26-vetsci-12-00089" ref-type="bibr">26</xref>,<xref rid="B27-vetsci-12-00089" ref-type="bibr">27</xref>]. Moreover, the cut-off was confirmed by another common method, according to which the best cut-off would be the OD value where the difference between sensitivity and specificity is smallest [<xref rid="B28-vetsci-12-00089" ref-type="bibr">28</xref>]. According to another study [<xref rid="B25-vetsci-12-00089" ref-type="bibr">25</xref>], the optimal cut-off may be a value between the maximum OD value of negative samples (Max OD&#x02212;) and the minimum OD value of positive samples (Min OD+). In addition, the Receiver Operating Characteristics (ROC) curve was used to identify the optimal cut-off value, the value that maximizes the difference between true positives and false positives. The ROC curve was constructed by joining the points obtained from the calculation of the proportion of true positives (sensitivity) and false positives (1-specificity) for all possible cut-off values. The point closest to the upper left corner of the ROC curve represented a good compromise between true and false positives and thus corresponded to the best cut-off. Closely related to the ROC curve method is the Youden&#x02019;s index (J). This index was calculated for each individual cut-off by the Formula (4):<disp-formula>J = sensitivity + specificity &#x02212; 1<label>(4)</label></disp-formula></p><p>The parameter J takes values in the closed range [0, 1]: value 0 corresponds to a completely ineffective test, while value 1 corresponds to a perfectly effective test. The best cut-off corresponds to the maximum value among the calculated indexes.</p><p>In addition, considering the amount of true positives (a), false positives (b), false negatives (c), and true negatives (d) obtained from the FIVCHECK Ab ELISA against the reference assay, all diagnostic parameters, including the accuracy, sensitivity, specificity, positive and negative predictive values (PPV and NPV), and positive and negative likelihood ratios (LR+ and LR&#x02212;) were determined at the selected cut-off value (Formulas (5)&#x02013;(11)). On the sensitivity, specificity, and PPV and NPV parameters, the 95% CI was also calculated.<disp-formula>Diagnostic accuracy = (a + d)/(a + b + c + d)<label>(5)</label></disp-formula><disp-formula>Sensitivity = a/(a + c)<label>(6)</label></disp-formula><disp-formula>Specificity = d/(b + d)<label>(7)</label></disp-formula><disp-formula>Positive predictive value (PPV) = a/(a + b)<label>(8)</label></disp-formula><disp-formula>Negative predictive values (NPV) = d/(c + d)<label>(9)</label></disp-formula><disp-formula>Positive likelihood ratio (LR+) = Sensitivity/(1 &#x02212; Specificity)<label>(10)</label></disp-formula><disp-formula>Negative likelihood ratio (LR&#x02212;) = (1 &#x02212; Sensitivity)/Specificity<label>(11)</label></disp-formula></p></sec><sec id="sec2dot9-vetsci-12-00089"><title>2.9. Statistical Analysis</title><p>Statistical analysis on results obtained from the comparative study was performed by ANOVA, by <italic toggle="yes">t</italic>-test considering significant a <italic toggle="yes">p</italic>-value &#x0003c; 0.05, and by calculating the Cohen&#x02019;s d index Equation (12) to measure the strength of the relationship (Effect size). M1 and M2 are the mean OD values of the two datasets and S1 and S2 are their standard deviations.<disp-formula>Cohen&#x02019;s d index = M1 &#x02212; M2/&#x0221a; (S1<sup>2</sup> + S2<sup>2</sup>)/2<label>(12)</label></disp-formula></p><p>In addition, for all comparison assays, the degree of agreement was calculated by Cohen&#x02019;s Kappa index Equation (13), where P<sub>0</sub> is the probability of agreement observed, and P<sub>e</sub> is that obtained by chance.<disp-formula>Cohen&#x02019;s Kappa index = P<sub>0</sub> &#x02212; P<sub>e</sub>/1 &#x02212; P<sub>e</sub><label>(13)</label></disp-formula></p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00089"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00089"><title>3.1. Plate Selection and General Assay Set-Up</title><p>PolySorp Nunc and Costar microplates (Thermo Fisher Scientific, Waltham, MA, USA) were coated with different concentrations from 0 &#x000b5;g/mL (non-coated plates) to 2 &#x000b5;g/mL of FIV recombinant antigen in CB buffer with a pH of 9.6 and blocked with Blocking Buffer 1 and Blocking Buffer 2. During ELISA preliminary assays, two samples (one positive and one negative) were diluted 1:100 in sample diluent, and the conjugate antibody anti-Cat IgG labeled with HRP was tested at different dilutions ranging from 1:2000 to 1:128,000. Non-coated plates (coating performed only with CB buffer) or coated plates tested only with the conjugate antibody diluent served as controls for aspecific binding. All diluted samples and the conjugate antibody were incubated for 10 min at RT in two successive incubations, then in the substrate TMB for 5 min at RT. Spectrophotometric readings on PolySorp Nunc and Costar microplates are shown in <xref rid="vetsci-12-00089-t001" ref-type="table">Table 1</xref>. All detailed OD values are reported in <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S1</xref>.</p><p>We obtained good results on all types of plates. Considering the instrumental readings, no statistically significant differences were found between PolySorp Nunc and Costar plates coated with FIV antigen and blocked with Blocking Buffer 1 or Blocking Buffer 2, testing both the positive and negative samples. Moreover, there were no aspecific bindings with coating components and conjugate antibody diluent: in all cases, tests performed with the two samples on non-coated plates or with only conjugate antibody diluent on coated ones resulted in low OD values (OD &#x0003c; 0.1). In addition, considering non-coated plates, we noted a statistically significant difference (<italic toggle="yes">p</italic>-value &#x0003c; 0.05) between PolySorp Nunc and Costar plates blocked with Blocking Buffer 2. In detail, only by testing the positive sample, the mean OD value on PolySorp Nunc plates was statistically significantly lower than on Costar ones. The effect size was 1.595, index of great difference (<xref rid="vetsci-12-00089-t002" ref-type="table">Table 2</xref>). Thus, we selected the PolySorp Nunc plates blocked with Blocking Buffer 2 for future assays, since the background signal on non-coated plates was less. Moreover, on this type of plate, we selected the 0.5 &#x000b5;g/mL of FIV antigen as the coating concentration and the 1:8000 conjugate antibody dilution because of the better performance on both the positive and negative samples, with OD values above 1.0 not over-flowing, and lower than 0.1, respectively. In subsequent assays, the performance of the test was verified by analyzing more samples.</p></sec><sec id="sec3dot2-vetsci-12-00089"><title>3.2. Sample Dilution Selection</title><p>To evaluate the best test performance, two sample dilutions were tested. At this purpose, samples were diluted 1:100 or 1:200 and the conjugate was used at dilution 1:8000. Samples and conjugate were incubated for 10 min at RT and TMB substrate for 5 min at RT, as in previous ELISAs. In all cases, we compared results with SNAP FIV/FeLV Combo (IDEXX) as the reference test. Initially, the cut-off was estimated in a general and simple manner as described in the literature [<xref rid="B23-vetsci-12-00089" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-12-00089" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00089" ref-type="bibr">25</xref>] as mean OD value of negative samples plus 3 times SD, thus considering positive samples with OD above the 10% cut-off, negative with OD below the 10% cut-off and doubtful with OD values between cut-off &#x000b1; 10%, as reported in other commercial ELISAs [<xref rid="B26-vetsci-12-00089" ref-type="bibr">26</xref>,<xref rid="B27-vetsci-12-00089" ref-type="bibr">27</xref>]. In the first ELISA performed on 58 feline samples (26 positives and 32 negatives) diluted 1:100, the cut-off value was set at OD 0.298; the ELISA correctly identified all positive samples. However, among negatives, six samples resulted in false positives (OD &#x0003e; 0.328) and one doubtful (OD values between 0.268 and 0.328). ELISA sensitivity was 100% and specificity was 81.3% (<xref rid="vetsci-12-00089-t003" ref-type="table">Table 3</xref>, <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S2</xref>). Instead, in the ELISA on 113 feline samples (37 positives and 76 negatives) diluted 1:200, the cut-off value was set at OD 0.343 and the test correctly identified all samples, 37 positives and 76 negatives, and, among negatives, one sample had OD value of 0.309, thus resulting in a &#x0201c;doubtful&#x0201d; categorization (OD values between 0.309 and 0.377). ELISA sensitivity and specificity were both 100% (<xref rid="vetsci-12-00089-t003" ref-type="table">Table 3</xref>, <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S3</xref>). In this context, the sample dilution 1:200 was selected because of better performances than the 1:100 one.</p></sec><sec id="sec3dot3-vetsci-12-00089"><title>3.3. Conjugate Dilution Selection</title><p>Despite good results obtained with conjugate antibody 1:8000, eight negative samples with SNAP FIV/FeLV Combo (IDEXX) assay had negative, but higher, OD values in our ELISA at dilution 1:200 (samples n. 28, 38, 39, 54, 57, 102, 104 and 108) (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S3</xref>). The results of SNAP FIV/FeLV Combo (IDEXX) on these eight samples are shown in <xref rid="vetsci-12-00089-f001" ref-type="fig">Figure 1</xref>. To further improve the signal of negative samples, we decreased the concentration of the anti-Cat IgG HRP conjugate antibody from 1:8000 to 1:15,000. An ELISA preliminary test was performed on 60 samples diluted 1:200 (28 positives and 32 negatives, including the previously doubtful sample obtained with conjugate 1:8000). Additionally, in this case, the cut-off was estimated as described in the literature [<xref rid="B23-vetsci-12-00089" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-12-00089" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00089" ref-type="bibr">25</xref>] as mean OD value of negative samples plus 3 times SD, thus we considered positive samples with OD above the 10% cut-off, negative with OD below the 10% cut-off, and doubtful with OD values between the cut-off &#x000b1;10%, as reported previously [<xref rid="B26-vetsci-12-00089" ref-type="bibr">26</xref>,<xref rid="B27-vetsci-12-00089" ref-type="bibr">27</xref>]. The cut-off value was set at OD 0.292; FIVCHECK Ab ELISA correctly identified all positive and negative samples without doubtful results, thus improving the signal of the eight negative samples with higher OD values than had been found previously (n. 53&#x02013;60) (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S4</xref>), in line with the results obtained with the SNAP FIV/FeLV Combo (IDEXX) assay. Since we obtained better results on negative samples even on those with higher OD values, in order to avoid losing the identification of any weakly positive samples, such as the number 27 with an OD value of 0.493 (conjugate 1:15,000) (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S4</xref>), we decided not to further dilute the conjugate antibody and thus maintain the 1:15,000 concentration for the validation phase and future tests.</p></sec><sec id="sec3dot4-vetsci-12-00089"><title>3.4. Positive and Negative Controls Evaluation</title><p>Since the recombinant antigen coated on the plate contains a histidine tail and no antibodies directed to the plate-immobilized antigen are commercially available, two anti-His antibodies, PC1 and PC2, were tested as positive controls. We tested different dilutions to obtain positive, quantifiable, and non-overflow values, at least with OD values above 0.6. In fact, in an ELISA that uses TMB as substrate, a weak positive signal appears visually in a very light blue color after the addition of TMB and with an OD value of about 0.3 at 450 nm. As reported in the bibliography, a strong positive control should have an OD &#x02265; 1.5 [<xref rid="B14-vetsci-12-00089" ref-type="bibr">14</xref>,<xref rid="B29-vetsci-12-00089" ref-type="bibr">29</xref>]. Both positive controls worked well. As expected, since PC1 and PC2 are not developed in cat, their signals do not depend on the anti-Cat IgG HRP conjugate antibody binding. In fact, we obtained similar results by testing PC1 both with 1:8000 and 1:15,000 conjugate antibody dilutions (<xref rid="vetsci-12-00089-t004" ref-type="table">Table 4</xref>). Finally, we chose the dilutions 1:8000 of PC1 and 1:60,000 of PC2 because of the strong but not overflowing signals for reproducibility and stability assays. However, the performance of PC2 as positive control was better than PC1 (<xref rid="vetsci-12-00089-t004" ref-type="table">Table 4</xref>), in terms of the amount of reagent to be used and thus the cost, thus PC2 was ultimately chosen as positive control.</p><p>Regarding the negative control, we performed an ELISA preliminary assay by testing the sample diluent 18 times both with 1:8000 and 1:15,000 conjugate antibody dilutions. We obtained good results, since the OD values were all below 0.1 and did not exceed the OD limit of 0.3 [<xref rid="B14-vetsci-12-00089" ref-type="bibr">14</xref>,<xref rid="B29-vetsci-12-00089" ref-type="bibr">29</xref>]. In fact, the mean OD values were 0.037 and 0.035 with 1:8000 and 1:15,000 conjugate antibody, respectively. Moreover, we tested negative samples diluted 1:200 both with conjugate 1:8000 (76 samples, the same used previously in the preliminary assay) and conjugate 1:15,000 (77 samples, used then in the validation phase) to verify that they gave a signal similar to that obtained with the sample diluent. As determined by data analysis, the mean OD value of the negative control fell within the range limit of between the mean OD and the standard deviation of negative samples with both 1:8000 (0.108 &#x000b1; 0.078) and 1:15,000 (0.076 &#x000b1; 0.051) conjugate dilutions (<xref rid="vetsci-12-00089-t004" ref-type="table">Table 4</xref>).</p><p>These results made the use of commercial reagents as positive and negative controls feasible, avoiding the use of sera as potentially infectious reagents in the final kit.</p></sec><sec id="sec3dot5-vetsci-12-00089"><title>3.5. ELISA Validation</title><p>The FIVCHECK Ab ELISA was validated against the reference test SNAP FIV/FeLV Combo (IDEXX), by using 115 samples (38 positives and 77 negatives). In the course of the study, highly lipemic and hemolytic samples were also tested, but no interferences were observed. Of 115 samples tested, the FIVCHECK Ab ELISA detected 38 positives and 77 negatives (<xref rid="vetsci-12-00089-t005" ref-type="table">Table 5</xref>, <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S5</xref>). The overall graph reporting the OD values of the data is shown in <xref rid="vetsci-12-00089-f002" ref-type="fig">Figure 2</xref>. Compared to the SNAP FIV/FeLV Combo test, the FIVCHECK Ab ELISA agreed at 100%, with 100% of sensitivity (95% CI: 88.5&#x02013;100%) and 100% of specificity (95% CI: 94.0&#x02013;100%). The Cohen&#x02019;s Kappa was 1.000, index of very good agreement. The PPV and the NPV were both 100%. Moreover, the negative likelihood ratio (LR&#x02212;) was 0.000, while the positive likelihood ratio (LR+) was impossible to calculate at OD &#x02265; 0.270 (cut-off), but it was very high at the previous OD of 0.260 (75.00).</p></sec><sec id="sec3dot6-vetsci-12-00089"><title>3.6. Cut-Off Evaluation</title><p>The cut-off of the FIVCHECK Ab ELISA was determined using 103 samples (37 positives and 66 negatives, sample numbers from 1 to 103, <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S5</xref>), considering the SNAP FIV/FeLV Combo (IDEXX) the reference test.</p><p>The cut-off estimated in our previous ELISAs, as described in the literature [<xref rid="B23-vetsci-12-00089" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-12-00089" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00089" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-12-00089" ref-type="bibr">26</xref>,<xref rid="B27-vetsci-12-00089" ref-type="bibr">27</xref>] as the mean OD value of negative samples plus 3 times the SD (positive samples: OD &#x02265; 10% cut-off; negative samples: OD &#x02264; 10% cut-off; doubtful samples: OD values between cut-off &#x000b1;10%), was confirmed by other methods.</p><p>Initially, the cut-off was evaluated on sensitivity and specificity parameters as reported in the bibliography [<xref rid="B28-vetsci-12-00089" ref-type="bibr">28</xref>]: in the FIVCHECK Ab ELISA, the best cut-off corresponded to an OD value of 0.270, which was the point at which the difference between sensitivity and specificity was minimal (difference equal to zero). At the cut-off with an OD value of 0.270, sensitivity and specificity were both 100%. Moreover, the same parameters were maintained up to a value of OD 0.530 (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S6</xref>, <xref rid="vetsci-12-00089-f003" ref-type="fig">Figure 3</xref>a). According to another study present in the literature [<xref rid="B25-vetsci-12-00089" ref-type="bibr">25</xref>], a correct cut-off may be a value between the maximum OD value of negative samples (Max OD&#x02212;) and the minimum OD value of positive samples (Min OD+). In the FIVCHECK Ab ELISA, Max OD&#x02212; was 0.261 and Min OD+ was 0.493. Based on the ROC curve, a statistical technique that identifies the optimal cut-off value, the best cut-off corresponded to an OD value of 0.270 (<xref rid="vetsci-12-00089-f003" ref-type="fig">Figure 3</xref>b), and, according to the Youden&#x02019;s index, the maximum calculated J value was 1.000 that coincided with the cut-off value with OD 0.270 (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S6</xref>, <xref rid="vetsci-12-00089-f003" ref-type="fig">Figure 3</xref>c). In conclusion, since all sensitivity and specificity parameters remained the same from the cut-off with OD 0.270 up to the cut-off with OD 0.530, an OD value of 0.300 was considered as the cut-off in the final assay. Samples with OD values between 0.230 and 0.300 were considered doubtful.</p></sec><sec id="sec3dot7-vetsci-12-00089"><title>3.7. Reproducibility Study</title><p>We performed a reproducibility study by testing the positive controls, PC1 (1:300) and PC2 (1:60,000), the NC, and one negative and two positive samples, in duplicate, twice in a day, for 14 consecutive days (56 tests for each sample) (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S7</xref>). The PC1 was tested only at dilution of 1:300 (reproducibility study was not performed on dilution 1:8000). In all cases, the FIVCHECK Ab ELISA was accurate, with intra- and inter-assay %CV lower than the 10% and 15&#x02013;20% limits, respectively, as reported in the bibliography [<xref rid="B22-vetsci-12-00089" ref-type="bibr">22</xref>,<xref rid="B30-vetsci-12-00089" ref-type="bibr">30</xref>] (<xref rid="vetsci-12-00089-t006" ref-type="table">Table 6</xref>, <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S8</xref>).</p></sec><sec id="sec3dot8-vetsci-12-00089"><title>3.8. Comparative Analysis</title><p>The newly developed test FIVCHECK Ab ELISA was compared with two other ELISA tests, the INgezim FIV ELISA (Gold Standard Diagnostics) and VetLine FIV (NovaTec) (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S9</xref>).</p><p>First, we performed ANOVA statistical analysis to determine whether there were any significant differences in the OD values of positive and negative samples between the 3 types of ELISA tests. In both categories of positive and negative samples, the F values were higher than the corresponding F critical values, therefore the mean OD values of the examined three ELISAs were not equal and at least one test was significantly different (<xref rid="vetsci-12-00089-t007" ref-type="table">Table 7</xref>). Then, to understand which test was statistically significantly different from FIVCHECK Ab ELISA, <italic toggle="yes">t</italic>-test (considering significant a <italic toggle="yes">p</italic>-value &#x0003c; 0.05) and Cohen&#x02019;s d index were evaluated.</p><sec id="sec3dot8dot1-vetsci-12-00089"><title>3.8.1. Comparative Study with INgezim FIV ELISA (Gold Standard Diagnostics)</title><p>All positive and negative samples were correctly identified, without false positives or false negatives, thus the new test agreed with INgezim FIV ELISA at 100% (Cohen&#x02019;s Kappa: 1.000, very good agreement) (<xref rid="vetsci-12-00089-t008" ref-type="table">Table 8</xref>). Statistical analysis performed on mean absorbance values between the two assays found a statistically significant difference only for positive samples: the mean OD values of positive samples in the FIVCHECK Ab ELISA were statistically significantly lower than those in the INgezim FIV ELISA. The Effect size calculated by Cohen&#x02019;s d gave a value of 1.956, index of great difference (<xref rid="vetsci-12-00089-t009" ref-type="table">Table 9</xref>; <xref rid="vetsci-12-00089-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec3dot8dot2-vetsci-12-00089"><title>3.8.2. Comparative Study with VetLine FIV ELISA (NovaTec)</title><p>Of 28 positive samples, the VetLine FIV ELISA identified 26 samples, while two resulted in false negatives (positives in both FIVCHECK Ab ELISA and INgezim FIV ELISA). Moreover, of 75 negative samples, the VetLine FIV ELISA identified 69 samples, while 6 were false positives (6 negatives in both FIVCHECK Ab ELISA and FIV INgezim FIV ELISA). One negative sample in both FIVCHECK Ab ELISA and FIV INgezim FIV ELISA was doubtful in VetLine FIV ELISA (<xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S9</xref>). Thus, the FIVCHECK Ab ELISA agreed with VetLine FIV ELISA at 92.2% (Cohen&#x02019;s Kappa: 0.812, very good agreement) (<xref rid="vetsci-12-00089-t008" ref-type="table">Table 8</xref>). Statistically significant differences were found between both positive and negative samples: in both categories, the mean OD values in the FIVCHECK Ab ELISA were statistically significantly lower than in VetLine FIV ELISA. The Effect size calculated by Cohen&#x02019;s d gave values of 0.781 (negatives) and 1.662 (positives), indices of moderate and great differences, respectively (<xref rid="vetsci-12-00089-t009" ref-type="table">Table 9</xref>; <xref rid="vetsci-12-00089-f004" ref-type="fig">Figure 4</xref>).</p></sec></sec><sec id="sec3dot9-vetsci-12-00089"><title>3.9. Stability Study</title><sec id="sec3dot9dot1-vetsci-12-00089"><title>3.9.1. Accelerated Stability Study</title><p>In the accelerated stability study, the PC1 (1:300 or 1:8000) and PC2 (1:60,000), the NC, and two negative and three positive samples were tested. Detailed data including spectrophotometric readings and percentage remaining activities (%RA) are shown in <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S10</xref>. We obtained good results in all tested times with a %RA above 70% (<xref rid="vetsci-12-00089-t010" ref-type="table">Table 10</xref>). However, only two samples had remaining activity values slightly below 70% at T<sub>6</sub> (sample 1, negative: 69.52%; sample 12, positive: 69.61%). However, at T<sub>6</sub>, the positive sample n.12 still had an OD value above the cut-off. Therefore, tests proved that all the reagents in the kit may be stable for 6 weeks at +37 &#x000b0;C and for 18 months at +2&#x02013;8 &#x000b0;C, data confirmed with the real-time stability tests.</p></sec><sec id="sec3dot9dot2-vetsci-12-00089"><title>3.9.2. Real-Time Stability Study</title><p>The real-time stability study lasted 18 months, and it was conducted with the same controls and samples already examined in the accelerated stability assays. Detailed data, including spectrophotometric readings and percentage remaining activities (%RA), are shown in <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Table S11</xref>. We confirmed the results obtained with the accelerated stability: the %RA remained high, above 70% (<xref rid="vetsci-12-00089-t011" ref-type="table">Table 11</xref>) in all tested time points, and proved that all the reagents in the kit are stable for 18 months at the normal storage temperature +2&#x02013;8 &#x000b0;C.</p></sec></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00089"><title>4. Discussion</title><p>Nunc PolySorp and Costar High Binding microplates were selected based on the Company&#x02019;s in-house ELISA testing experience, and, supported by a large bibliography, used in the set-up of the test in order to choose the plate capable of providing the most accurate results. Both types of plates are commonly used in general ELISAs to immobilize antigens or antibodies. Costar High Binding microplates have hydrophobic surfaces that permit the immobilization of both medium and large biomolecules that possess ionic groups and/or hydrophobic regions. They were used both in antigens&#x02019; [<xref rid="B31-vetsci-12-00089" ref-type="bibr">31</xref>,<xref rid="B32-vetsci-12-00089" ref-type="bibr">32</xref>] and antibodies&#x02019; [<xref rid="B33-vetsci-12-00089" ref-type="bibr">33</xref>,<xref rid="B34-vetsci-12-00089" ref-type="bibr">34</xref>,<xref rid="B35-vetsci-12-00089" ref-type="bibr">35</xref>] coatings. Additionally, Nunc PolySorp plates have hydrophobic surfaces and permit the adsorption of hydrophobic molecules. They were used to immobilize both antigens [<xref rid="B36-vetsci-12-00089" ref-type="bibr">36</xref>,<xref rid="B37-vetsci-12-00089" ref-type="bibr">37</xref>] or antibodies [<xref rid="B38-vetsci-12-00089" ref-type="bibr">38</xref>] in ELISAs. However, after several tests conducted in parallel with both types of plates under analogous conditions without further variables, Nunc PolySorp microplates were chosen because of better performance results.</p><p>The FIVCHECK Ab ELISA was validated against the ELISA rapid test SNAP FIV/FeLV Combo (IDEXX), considered the reference test, by testing feline sera including positive and negative samples. The SNAP FIV/FeLV Combo (IDEXX) assay was chosen as reference method for the ELISA validation for different reasons:<list list-type="order"><list-item><p>SNAP FIV/FeLV Combo is a qualitative ELISA test, as well as FIVCHECK Ab ELISA;</p></list-item><list-item><p>SNAP FIV/FeLV Combo is a lateral flow ELISA that uses the FIV matrix protein p15, the capsid protein p24, and the transmembrane glycoprotein gp40 as antigens to detect FIV antibodies. Moreover, it contains monoclonal anti-FeLV p27 antibodies to detect FeLV p27 antigen [<xref rid="B39-vetsci-12-00089" ref-type="bibr">39</xref>,<xref rid="B40-vetsci-12-00089" ref-type="bibr">40</xref>,<xref rid="B41-vetsci-12-00089" ref-type="bibr">41</xref>]. However, FIVCHECK Ab ELISA uses only a recombinant antigen derived from envelope transmembrane glycoprotein gp40 because it is considered the immunodominant protein in FIV infection, instead of p15 and p24, which may be less specific for FIV and may be the result of infection with other viruses [<xref rid="B42-vetsci-12-00089" ref-type="bibr">42</xref>];</p></list-item><list-item><p>SNAP FIV/FeLV Combo has high sensitivity (99.2%) and high specificity (100%) for the detection of FIV antibodies [<xref rid="B39-vetsci-12-00089" ref-type="bibr">39</xref>]. In fact, for the FIV test systems, the PPV of the FIV/FeLV Combo test was very high compared to other microplate ELISA tests such as PetChek FIV antibody test (IDEXX) and Virachek FIV (Synbiotics). The PetChek FIV test contains FIV p24 and gp40 antigens, instead the Virachek FIV assay only the p24 [<xref rid="B43-vetsci-12-00089" ref-type="bibr">43</xref>]. Moreover, in a study comparing four different FIV tests using FIV-positive and FIV-negative samples, sensitivity and specificity of the SNAP FIV/FeLV Combo were 97.9% and 99.0%, respectively, compared with virus isolation as the gold standard [<xref rid="B9-vetsci-12-00089" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-12-00089" ref-type="bibr">10</xref>] and PCR [<xref rid="B44-vetsci-12-00089" ref-type="bibr">44</xref>];</p></list-item><list-item><p>The performance of SNAP FIV/FeLV Combo assay is comparable to that of the two most currently available tests for FIV immunochromatography assay: Witness FeLV/FIV (Zoetis, Parsippany-Troy Hills, NJ, USA) and Anigen Rapid FIV/FeLV (BioNote, Hwaseong-si, Gyeonggi-do, Republic of Korea) [<xref rid="B40-vetsci-12-00089" ref-type="bibr">40</xref>].</p></list-item></list></p><p>Compared with the SNAP FIV/FeLV Combo (IDEXX), the FIVCHECK Ab ELISA correctly identified FIV positive and negative samples with very high sensitivity (100%, 95% CI: 88.5&#x02013;100%) and high specificity (100%, 95% CI: 94.0&#x02013;100%).</p><p>Interpretation of the results was performed instrumentally. From data analysis, the FIVCHECK Ab ELISA cut-off was set at OD 0.300, and, in the final kit, the user will determine the positivity or negativity of the samples by calculating the &#x0201c;negative cut-off&#x0201d; and &#x0201c;positive cut-off&#x0201d; formulas based on the OD value of the negative control. Thus, the sample will be considered negative if the OD value is lower than negative cut-off, positive if the OD value is greater than the positive cut-off, and doubtful if the OD value is between the two cut-offs. In this latter instance, it is recommended to repeat the analysis or take another sample a couple of weeks later.</p><p>No interference was observed on highly lipemic or hemolytic samples collected in different types of anticoagulants in the FIVCHECK Ab ELISA. However, the presence of ELISA-interfering substances, including drugs or natural compounds, in the blood of cats with profound inflammation or immune activation should be explored. In this regard, we did not perform extensive studies to verify cross-reactivity reactions, partly due to a lack of representative samples, which are difficult to find.</p><p>We did not report false positive or false negative results. In antibody assays using indirect ELISA, false positive and negative reactions can occur due to various reasons unrelated to the antigens coated to the plate. In fact, during sample preparation, errors such as sample collection, storage, handling, and processing contamination can interfere with the accuracy of the test results. Generally, ELISA false positive reactions may be caused by nonspecific reactivity and background noise resulting from the binding of antigens or immunoglobulins in the sample specimens to the solid phase. In addition, cross-reactivity reactions may occur when ELISA test detects antibodies or antigens that are similar to, but not identical to, the target antigen or antibody. However, this reaction is dependent on each sample and can vary significantly, sometimes even surpassing the true antibody&#x02013;antigen reaction. Although we tested a large number of samples, this step is sample-dependent and difficult to predict.</p><p>FIV false positive results may occur in uninfected FIV-vaccinated cats. For this reason, the ELISA antibody assays for the detection of FIV antibodies alone cannot be used to distinguish FIV-vaccinated/FIV-uninfected cats from FIV-infected cats. In addition, maternally derived anti-FIV antibodies may be present in kittens for up to 3 months, and it may be a further two months before infected kittens seroconvert [<xref rid="B5-vetsci-12-00089" ref-type="bibr">5</xref>]. Moreover, the exposure to off-target pathogens may elicit antibodies that may non-specifically bind to antigens used in ELISAs. In a study reported in the literature, domestic cats with multiple pathogen exposures and ongoing infections resulted in antibodies that cross-reacted non-specifically with the FIV Gag antigen. In that case, 3 of 12 FIV infected cats had higher seroreactivity to the Gag antigen of the retrovirus feline foamy virus (FFV) [<xref rid="B45-vetsci-12-00089" ref-type="bibr">45</xref>]. Cross-reaction studies in cats were observed by testing other feline lentiviruses compared with FIV, such as puma lentivirus PLV-A and PLV-B or lion lentivirus FIV<sub>Ple</sub>, which typically resulted in lower levels of plasma viremia than host-adapted FIV strains [<xref rid="B46-vetsci-12-00089" ref-type="bibr">46</xref>]. In another study, PLV and FIV co-infected cats had delayed FIV proviral or RNA load detection in blood and had accelerated anti-FIV capsid antibody development when compared to cats with single PLV or single FIV infection [<xref rid="B47-vetsci-12-00089" ref-type="bibr">47</xref>]. However, FIV positive cats tested with the FIV ELISA based on FIV Gag and gp40 antigens were negative in PLV ELISA and PLV Western blot, suggesting the absence of cross-reactivity [<xref rid="B48-vetsci-12-00089" ref-type="bibr">48</xref>].</p><p>Regarding false negative results, they may occur early in the disease before there is a sufficient antibody response or late in the disease when the cat is severely immunosuppressed [<xref rid="B49-vetsci-12-00089" ref-type="bibr">49</xref>]. Considering the animal&#x02019;s clinical signs, false positive and false negative FIV tests should be retested after a few weeks or confirmed by another assay, such as IFA, PCR, or Western blot.</p><p>No information was provided about breed, sex, age, clinical outcomes, disease progression, or treatments of patients with drugs, thus no sample selection was performed in order to contemplate the broadest possible cases. In this way, we also simulated the case of clinicians who might analyze specimens from patients with unknown diagnoses or general conditions. Therefore, our ELISA resulted independently from physiological and pathological conditions of the patient animal. However, further clinical experience and additional patient outcome data will help to reveal more about the specific mechanisms underlying cross-reactive antibody production. In this context, additional future work could be directed to exploring factors that may impact test results.</p><p>Although a real-world study is lacking, the company has not received any reports of test malfunction by end-users since the product was put on the market (two years). The test&#x02019;s correct functioning is evidenced by a recent study reported in the literature in which feline samples were analyzed for FIV antibodies first by lateral flow assay, then confirmed by using the FIVCHECK Ab ELISA [<xref rid="B50-vetsci-12-00089" ref-type="bibr">50</xref>].</p><p>The new ELISA is an accurate assay with intra- and inter-assay %CV lower than 20%, defined as the limit of acceptable %CV for precision and accuracy in the general guidelines [<xref rid="B22-vetsci-12-00089" ref-type="bibr">22</xref>,<xref rid="B30-vetsci-12-00089" ref-type="bibr">30</xref>]. Regarding ELISA kit controls, we evaluated commercial reagents for reasons related to future production needs and safety for the end-user. In fact, the availability of samples, especially positives to be used as positive controls, is limited, and the amount to be collected and put in the final kit during test production would be too much. In addition, the use of serum/plasma as control (especially positive) might result in variability and lack of homogeneity between batches due to the nature of the sample (strong positive or weak positive). Moreover, to ensure operator safety, it is good practice to avoid the use of samples that are potentially infected, so we included in the kit only commercial reagents certified as non-infectious.</p><p>Histidine tags are characterized by low immunogenicity, small size, and are indispensable tools in many research laboratories, as typically they are the most widely used affinity tags for purifying recombinant proteins under both native and denaturing conditions [<xref rid="B51-vetsci-12-00089" ref-type="bibr">51</xref>]. In our case, since the FIV antigen coated on the plate contains a histidine tail and no antibodies directed to the plate-immobilized antigen are commercially available, two anti-His antibodies were tested as positive controls. The use of antibodies that bind to His-tagged proteins has been reported in the literature [<xref rid="B52-vetsci-12-00089" ref-type="bibr">52</xref>,<xref rid="B53-vetsci-12-00089" ref-type="bibr">53</xref>,<xref rid="B54-vetsci-12-00089" ref-type="bibr">54</xref>,<xref rid="B55-vetsci-12-00089" ref-type="bibr">55</xref>]. In order to obtain a strong positive control, a minimum OD value of 0.6 was chosen for test validity as reported in bibliography [<xref rid="B14-vetsci-12-00089" ref-type="bibr">14</xref>,<xref rid="B29-vetsci-12-00089" ref-type="bibr">29</xref>] and in ELISAs [<xref rid="B56-vetsci-12-00089" ref-type="bibr">56</xref>,<xref rid="B57-vetsci-12-00089" ref-type="bibr">57</xref>,<xref rid="B58-vetsci-12-00089" ref-type="bibr">58</xref>]. Although both reagents tested gave good results, we demonstrated that PC2 might be an excellent positive control in FIVCHECK Ab ELISA because of the best performances.</p><p>Instead, the negative control should not exceed an OD of 0.3 [<xref rid="B14-vetsci-12-00089" ref-type="bibr">14</xref>,<xref rid="B29-vetsci-12-00089" ref-type="bibr">29</xref>] and, in our developed ELISA, sample diluent used as the negative control always gave OD values below 0.1. It is known that PBS-based solutions are used as negative controls both in ELISA tests developed for research purposes and in commercially available assays [<xref rid="B59-vetsci-12-00089" ref-type="bibr">59</xref>,<xref rid="B60-vetsci-12-00089" ref-type="bibr">60</xref>,<xref rid="B61-vetsci-12-00089" ref-type="bibr">61</xref>,<xref rid="B62-vetsci-12-00089" ref-type="bibr">62</xref>,<xref rid="B63-vetsci-12-00089" ref-type="bibr">63</xref>]. Here, we demonstrated the feasibility of using sample diluent as the negative control. In fact, the mean OD value of the negative control fell within the range limit obtained by analyzing negative samples with both 1:8000 and 1:15,000 conjugate dilutions.</p><p>A comparative study was performed by analyzing samples with two other rapid indirect ELISA tests widely used in the literature, the INgezim FIV ELISA (Gold Standard Diagnostics) [<xref rid="B64-vetsci-12-00089" ref-type="bibr">64</xref>,<xref rid="B65-vetsci-12-00089" ref-type="bibr">65</xref>] and VetLine FIV ELISA (NovaTec) [<xref rid="B66-vetsci-12-00089" ref-type="bibr">66</xref>,<xref rid="B67-vetsci-12-00089" ref-type="bibr">67</xref>,<xref rid="B68-vetsci-12-00089" ref-type="bibr">68</xref>]. Excellent agreement (100%, Cohen&#x02019;s Kappa of 1.000) resulted from the comparative study, with INgezim FIV ELISA as all positive and negative samples were correctly identified, without false positives or false negatives. Instead, very good agreement was found with VetLine FIV ELISA at 92.2% (Cohen&#x02019;s Kappa: 0.812), even if two samples resulted in false negatives and six false positives. However, we found a statistically significant difference between both positive and negative samples among the three compared ELISA tests. In particular, in FIVCHECK Ab ELISA, positive samples had statistically significant lower OD values compared to INgezim FIV and VetLine FIV, with great differences (Effect sizes of 1.956 and 1.662, respectively). In addition, negative samples had significantly lower OD values in FIVCHECK Ab ELISA compared with the VetLine FIV (Effect size of 0.781, moderate difference). In this context, in the FIVCHECK Ab ELISA, results may appear clearer and could be interpreted in a better way.</p><p>The ELISA kit must be refrigerated at +2&#x02013;8 &#x000b0;C to ensure its stability from production to use. However, accelerated stability is normally performed at +37 &#x000b0;C to accelerate the chemical or physical reactions of the biological reagents [<xref rid="B69-vetsci-12-00089" ref-type="bibr">69</xref>,<xref rid="B70-vetsci-12-00089" ref-type="bibr">70</xref>], and it is the most suitable method for simulate product degradation and thus to determine its expiration quickly, without waiting a long period for degradation to actually occur. In fact, many unexpected factors, such as cold chain breakage, may arise during transportation or storage, and they may negatively impact the quality and performance of the product.</p><p>The climatic zones where the products are sold determine the storage conditions that should be used. Depending on country-specific regulations, stability tests may need to be conducted at defined temperatures reflecting the respective climate zone of the country in which it is intended to market. If the product is stable under the storage conditions of the hotter climatic zone, then it is automatically suitable for use in colder zones [<xref rid="B71-vetsci-12-00089" ref-type="bibr">71</xref>,<xref rid="B72-vetsci-12-00089" ref-type="bibr">72</xref>]. The temperature of +37 &#x000b0;C simulates that of hotter climate zones; thus, at the end of stability testing, the product can be marketed in all climate zones, including III (hot and dry climate) and IV (hot and humid/very humid climate).</p><p>In contrast to pharmaceutical products or veterinary drugs for which there are present guidelines for stability testing [<xref rid="B73-vetsci-12-00089" ref-type="bibr">73</xref>,<xref rid="B74-vetsci-12-00089" ref-type="bibr">74</xref>], the prediction of the shelf-life related to veterinary diagnostic kits (ELISA or immunochromatographic assays) does not refer to any specific legislation or regulations. In the absence of standards regarding stability tests related to veterinary diagnostic kits, reference was made to existing methods used for medical devices. In particular, we utilized the Standard Guide for Accelerated Aging of Sterile Medical Device Packages ASTM F1980-21 [<xref rid="B19-vetsci-12-00089" ref-type="bibr">19</xref>] that uses the Arrhenius equation to estimate the degradation of a medical device under accelerated conditions and represents an equivalent real-time shelf-life duration. According to this guideline, stability studies conducted on the FIVCHECK Ab ELISA demonstrated that the kit is stable for 18 months at +2&#x02013;8 &#x000b0;C and for 6 weeks at +37 &#x000b0;C. This makes the product suitable for use even in hotter climate zones and in conditions of possible cold chain breakage for up to 6 weeks.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00089"><title>5. Conclusions</title><p>This study demonstrates that the FIVCHECK Ab ELISA is an accurate test characterized by high sensitivity and specificity. The new FIVCHECK Ab ELISA provided correct and reliable results very quickly (25 min) without the need for thermostats. The interpretation of results is performed instrumentally by reading the OD values at 450 nm using an ELISA microplate reader. The new test is also suitable for the analysis of highly lipemic or hemolytic samples, as no interferences were observed. The new ELISA contains safe reagents for the end-user and has a long-term storage up to 18 months at +2&#x02013;8 &#x000b0;C. All these features make this test optimal for use in veterinary practice.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Paola Dall&#x02019;Ara and Joel Filipe from Department of Veterinary Medicine and Animal Sciences of University of Milan for their review of data and the final version of this manuscript. Moreover, the authors are grateful to all participants who agreed to join the project. Among them, thanks are extended to Italian veterinary practices and clinics that collaborated in the specimen collection (Veterinary Center of Lungo Dora Colletta, Turin; Veterinary Center Dr. Vassia of Romano Canavese, Turin; Genefast srl, Forl&#x000ec;; Veterinary Center &#x0201c;Amici per sempre&#x0201d;, Rome).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00089"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="www.mdpi.com/article/10.3390/vetsci12020089/s1">www.mdpi.com/article/10.3390/vetsci12020089/s1</uri>, Supplementary Table S1. ELISA preliminary assays. Supplementary Table S2. Results of FIVCHECK Ab ELISA (sample dilution 1:100) against the SNAP FIV/FeLV Combo (IDEXX). Supplementary Table S3. Results of FIVCHECK Ab ELISA (sample dilution 1:200) against the SNAP FIV/FeLV Combo (IDEXX). Supplementary Table S4. Conjugate antibody selection in FIVCHECK Ab ELISA. Supplementary Table S5. Validation results of FIVCHECK Ab ELISA against the reference test SNAP FIV/FeLV Combo (IDEXX). Supplementary Table S6. Cut-off determination. Supplementary Table S7. Reproducibility study. Supplementary Table S8. Intra- and inter-assay coefficient of variation of FIVCHECK Ab ELISA. Supplementary Table S9. Comparison results of FIVCHECK Ab ELISA, INgezim FIV and VetLine. Supplementary Table S10. Accelerated stability study. Supplementary Table S11. Real-time stability study.</p><supplementary-material id="vetsci-12-00089-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00089-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>I.F., P.P. and E.G.: conceptualization, methodology, software, validation; I.F., P.P. and E.G.: formal analysis, investigation, resources, data curation; I.F., P.P. and E.G.: writing&#x02014;original draft preparation; J.F. and P.D.: writing&#x02014;review, editing, visualization, supervision. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study does not involve humans. It was conducted only on serum or plasma samples collected from cats presented for diagnostic evaluation in veterinary practices and clinics in agreement with the owners. The study was reviewed and approved by the Faculty of Veterinary Medicine, University of Milan, Department of Veterinary Medicine and Animal Sciences.</p></notes><notes><title>Informed Consent Statement</title><p>This study does not involve human participants. However, animal samples (feline serum/plasma) used in this study were kindly collected by clinicians during normal routine analysis in agreement with the owners and gently donated for the successful completion of the project.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are available in this published article and as <xref rid="app1-vetsci-12-00089" ref-type="app">Supplementary Information</xref>. Datasets generated during the current study are also available from the corresponding author on reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Authors Irene Ferrero, Paolo Poletti and Enrica Giachino were employed by the company Agrolabo S.p.A. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00089"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bollo</surname><given-names>E.</given-names></name>
<name><surname>Allione</surname><given-names>A.</given-names></name>
<name><surname>Bo</surname><given-names>S.</given-names></name>
<name><surname>Vozza</surname><given-names>M.</given-names></name>
<name><surname>Lopez</surname><given-names>I.L.</given-names></name>
</person-group><article-title>Evaluation of rapid immunochromatographic tests for serological diagnosis of Feline Immunodeficiency Virus and Feline Leukemia Virus infection in cats</article-title><source>J. Anim. Vet. Adv.</source><year>2003</year><volume>2</volume><fpage>496</fpage><lpage>501</lpage></element-citation></ref><ref id="B2-vetsci-12-00089"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohammadi</surname><given-names>H.</given-names></name>
<name><surname>Bienzle</surname><given-names>D.</given-names></name>
</person-group><article-title>Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV)</article-title><source>Viruses</source><year>2012</year><volume>4</volume><fpage>708</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.3390/v4050708</pub-id><pub-id pub-id-type="pmid">22754645</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00089"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elder</surname><given-names>J.H.</given-names></name>
<name><surname>Lin</surname><given-names>Y.C.</given-names></name>
<name><surname>Fink</surname><given-names>E.</given-names></name>
<name><surname>Gran</surname><given-names>C.K.</given-names></name>
</person-group><article-title>Feline Immunodeficiency Virus (FIV) as A Model for Study of Lentivirus Infections: Parallels with HIV</article-title><source>Curr. HIV Res.</source><year>2010</year><volume>8</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2174/157016210790416389</pub-id><pub-id pub-id-type="pmid">20210782</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00089"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westman</surname><given-names>M.E.</given-names></name>
<name><surname>Malik</surname><given-names>R.</given-names></name>
<name><surname>Norris</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Diagnosing feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) infection: An update for clinicians</article-title><source>Aust. Vet. J.</source><year>2019</year><volume>97</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/avj.12781</pub-id><pub-id pub-id-type="pmid">30809813</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00089"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westman</surname><given-names>M.E.</given-names></name>
<name><surname>Coggins</surname><given-names>S.J.</given-names></name>
<name><surname>van Dorsselaer</surname><given-names>M.</given-names></name>
<name><surname>Norris</surname><given-names>J.M.</given-names></name>
<name><surname>Squires</surname><given-names>R.A.</given-names></name>
<name><surname>Thompson</surname><given-names>M.</given-names></name>
<name><surname>Malik</surname><given-names>R.</given-names></name>
</person-group><article-title>Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management</article-title><source>Aust. Vet. J.</source><year>2022</year><volume>100</volume><fpage>345</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1111/avj.13166</pub-id><pub-id pub-id-type="pmid">35578381</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00089"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rolph</surname><given-names>K.E.</given-names></name>
<name><surname>Cavanaugh</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Infectious Causes of Neoplasia in the Domestic Cat</article-title><source>Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>467</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci9090467</pub-id><pub-id pub-id-type="pmid">36136683</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00089"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>S.</given-names></name>
<name><surname>Arshad</surname><given-names>M.I.</given-names></name>
<name><surname>Akhtar</surname><given-names>F.</given-names></name>
<name><surname>Saqib</surname><given-names>M.</given-names></name>
<name><surname>Aslam</surname><given-names>R.</given-names></name>
<name><surname>Abbas</surname><given-names>G.</given-names></name>
<name><surname>Ashraf</surname><given-names>M.</given-names></name>
<name><surname>Rahman</surname><given-names>S.U.</given-names></name>
</person-group><article-title>Seroprevalence and risk factor association of feline immunodeficiency virus in cats</article-title><source>Pak. Vet. J.</source><year>2017</year><volume>37</volume><fpage>368</fpage><lpage>371</lpage></element-citation></ref><ref id="B8-vetsci-12-00089"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartmann</surname><given-names>K.</given-names></name>
</person-group><article-title>Clinical Aspects of Feline Retroviruses: A Review</article-title><source>Viruses</source><year>2012</year><volume>4</volume><fpage>2684</fpage><lpage>2710</lpage><pub-id pub-id-type="doi">10.3390/v4112684</pub-id><pub-id pub-id-type="pmid">23202500</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00089"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levy</surname><given-names>J.K.</given-names></name>
<name><surname>Crawford</surname><given-names>P.C.</given-names></name>
<name><surname>Tucker</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Performance of 4 point-of-care screening tests for feline leukemia virus and feline immunodeficiency virus</article-title><source>J. Vet. Intern. Med.</source><year>2017</year><volume>31</volume><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1111/jvim.14648</pub-id><pub-id pub-id-type="pmid">28158913</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00089"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Little</surname><given-names>S.</given-names></name>
<name><surname>Levy</surname><given-names>J.</given-names></name>
<name><surname>Hartmann</surname><given-names>K.</given-names></name>
<name><surname>Hofmann-Lehmann</surname><given-names>R.</given-names></name>
<name><surname>Hosie</surname><given-names>M.</given-names></name>
<name><surname>Olah</surname><given-names>G.</given-names></name>
<name><surname>St Denis</surname><given-names>K.</given-names></name>
</person-group><article-title>2020 AAFP Feline Retrovirus Testing and Management Guidelines</article-title><source>J. Feline Med. Surg.</source><year>2020</year><volume>22</volume><fpage>5</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1177/1098612X19895940</pub-id><pub-id pub-id-type="pmid">31916872</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00089"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Biomol GmbH, Bethyl Laboratories Inc</collab>
</person-group><article-title>ELISA Protocol</article-title><comment>Available online: <ext-link xlink:href="https://www.biomol.com/dateien/Bethyl--ELISA-Protocol.pdf" ext-link-type="uri">https://www.biomol.com/dateien/Bethyl--ELISA-Protocol.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-09-13">(accessed on 13 September 2022)</date-in-citation></element-citation></ref><ref id="B12-vetsci-12-00089"><label>12.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Cusabio Tachnology LLC</collab>
</person-group><article-title>ELISA Protocols</article-title><comment>Available online: <ext-link xlink:href="https://www.cusabio.com/protocols/ELISA_Protocol.pdf" ext-link-type="uri">https://www.cusabio.com/protocols/ELISA_Protocol.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-10-25">(accessed on 25 October 2022)</date-in-citation></element-citation></ref><ref id="B13-vetsci-12-00089"><label>13.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>GeneTex</collab>
</person-group><article-title>Protocol: Indirect ELISA</article-title><comment>Available online: <ext-link xlink:href="https://www.genetex.com/upload/media/support/protocols/genetex_ELISA(indirect).pdf" ext-link-type="uri">https://www.genetex.com/upload/media/support/protocols/genetex_ELISA(indirect).pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-16">(accessed on 16 December 2022)</date-in-citation></element-citation></ref><ref id="B14-vetsci-12-00089"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Appeltrath</surname><given-names>G.A.</given-names></name>
<name><surname>Parreuter</surname><given-names>J.</given-names></name>
<name><surname>Lindemann</surname><given-names>M.</given-names></name>
<name><surname>Klump</surname><given-names>H.</given-names></name>
<name><surname>Karsten</surname><given-names>C.B.</given-names></name>
</person-group><article-title>An efficient ELISA protocol for measurement of SARS-CoV-2 spike-specific IgG in human plasma and serum samples</article-title><source>MethodsX</source><year>2024</year><volume>12</volume><fpage>102596</fpage><pub-id pub-id-type="doi">10.1016/j.mex.2024.102596</pub-id><pub-id pub-id-type="pmid">38379717</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00089"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mei</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>P.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
<name><surname>Shao</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
</person-group><article-title>Development and application of an antigen capture ELISA assay for diagnosis of Japanese encephalitis virus in swine, human and mosquito</article-title><source>Virol. J.</source><year>2012</year><volume>9</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-9-4</pub-id><pub-id pub-id-type="pmid">22221768</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00089"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Righi</surname><given-names>C.</given-names></name>
<name><surname>Iscaro</surname><given-names>C.</given-names></name>
<name><surname>Ferroni</surname><given-names>L.</given-names></name>
<name><surname>Rosati</surname><given-names>S.</given-names></name>
<name><surname>Pellegrini</surname><given-names>C.</given-names></name>
<name><surname>Nogarol</surname><given-names>C.</given-names></name>
<name><surname>Rossi</surname><given-names>E.</given-names></name>
<name><surname>Dettori</surname><given-names>A.</given-names></name>
<name><surname>Feliziani</surname><given-names>F.</given-names></name>
<name><surname>Petrini</surname><given-names>S.</given-names></name>
</person-group><article-title>Validation of a Commercial Indirect ELISA Kit for the Detection of Bovine alphaherpesvirus 1 (BoHV-1)-Specific Glycoprotein E Antibodies in Bulk Milk Samples of Dairy Cows</article-title><source>Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>311</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci9070311</pub-id><pub-id pub-id-type="pmid">35878328</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00089"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Z.</given-names></name>
<name><surname>Houchins</surname><given-names>D.</given-names></name>
<name><surname>Ung</surname><given-names>J.</given-names></name>
<name><surname>Richard</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Validation of an ELISA test kit for the detection of deoxynivalenol in several food commodities</article-title><source>JSM Mycotoxins</source><year>2003</year><volume>2003</volume><issue>(Suppl. S3)</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.2520/myco1975.2003.Suppl3_295</pub-id><pub-id pub-id-type="pmid">39833224</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00089"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Organisation for Animal Health (WOAH)</collab>
</person-group><article-title>Principles and methods of validation of diagnostic assays for infectious diseases</article-title><source>Terrestrial Manual</source><edition>12th ed.</edition><publisher-name>WOAH</publisher-name><publisher-loc>Paris, France</publisher-loc><year>2023</year><comment>Chapter 1.1.6</comment><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="B19-vetsci-12-00089"><label>19.</label><element-citation publication-type="book"><std>ASTM F1980-21</std><source>Standard for Accelerated Aging of Sterile Barrier Systems and Medical Devices</source><publisher-name>ASTM International</publisher-name><publisher-loc>West Conshohocken, PA, USA</publisher-loc><year>2021</year><pub-id pub-id-type="doi">10.1520/F1980-21</pub-id></element-citation></ref><ref id="B20-vetsci-12-00089"><label>20.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Keystone Compliance</collab>
</person-group><article-title>Accelerated Aging Time Calculator</article-title><year>2019</year><comment>Available online: <ext-link xlink:href="https://keystonecompliance.com/aat-calculator/" ext-link-type="uri">https://keystonecompliance.com/aat-calculator/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-20">(accessed on 20 February 2023)</date-in-citation></element-citation></ref><ref id="B21-vetsci-12-00089"><label>21.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Packaging Compliance Labs</collab>
</person-group><article-title>Accelerated Aging Calculator</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://pkgcompliance.com/resource/accelerated-aging-calculator/" ext-link-type="uri">https://pkgcompliance.com/resource/accelerated-aging-calculator/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-20">(accessed on 20 February 2023)</date-in-citation></element-citation></ref><ref id="B22-vetsci-12-00089"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lexmond</surname><given-names>W.</given-names></name>
<name><surname>van der Mee</surname><given-names>J.</given-names></name>
<name><surname>Ruiter</surname><given-names>F.</given-names></name>
<name><surname>Platzer</surname><given-names>B.</given-names></name>
<name><surname>Stary</surname><given-names>G.</given-names></name>
<name><surname>Yen</surname><given-names>E.H.</given-names></name>
<name><surname>Dehlink</surname><given-names>E.</given-names></name>
<name><surname>Nurko</surname><given-names>S.</given-names></name>
<name><surname>Fiebiger</surname><given-names>E.</given-names></name>
</person-group><article-title>Development and validation of a standardized ELISA for the detection of soluble Fc-epsilon-RI in human serum</article-title><source>J. Immunol. Methods</source><year>2011</year><volume>373</volume><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2011.08.018</pub-id><pub-id pub-id-type="pmid">21903095</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00089"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Shang</surname><given-names>H.</given-names></name>
<name><surname>Niu</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Miao</surname><given-names>Y.</given-names></name>
<name><surname>Sha</surname><given-names>Z.</given-names></name>
<name><surname>Qin</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Peng</surname><given-names>D.</given-names></name>
<name><surname>Zhu</surname><given-names>R.</given-names></name>
</person-group><article-title>Establishment and evaluation of an indirect ELISA for detection of antibodies to goat Klebsiella pneumonia</article-title><source>BMC Vet. Res.</source><year>2021</year><volume>17</volume><elocation-id>107</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-021-02820-1</pub-id><pub-id pub-id-type="pmid">33663505</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00089"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khatri</surname><given-names>S.</given-names></name>
<name><surname>Psaraftis</surname><given-names>N.</given-names></name>
<name><surname>Funaro</surname><given-names>A.</given-names></name>
<name><surname>Arinuma</surname><given-names>Y.</given-names></name>
<name><surname>Fujieda</surname><given-names>Y.</given-names></name>
<name><surname>Mader</surname><given-names>S.</given-names></name>
<name><surname>J&#x000f8;rgensen</surname><given-names>C.D.</given-names></name>
<name><surname>Astakhova</surname><given-names>K.</given-names></name>
</person-group><article-title>Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens</article-title><source>J. Transl. Autoimmun.</source><year>2020</year><volume>3</volume><fpage>100068</fpage><pub-id pub-id-type="doi">10.1016/j.jtauto.2020.100068</pub-id><pub-id pub-id-type="pmid">33205038</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00089"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lardeux</surname><given-names>F.</given-names></name>
<name><surname>Torrico</surname><given-names>G.</given-names></name>
<name><surname>Aliaga</surname><given-names>C.</given-names></name>
</person-group><article-title>Calculation of the ELISA&#x02019;s cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls</article-title><source>Mem&#x000f3;rias Inst. Oswaldo Cruz</source><year>2016</year><volume>111</volume><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1590/0074-02760160119</pub-id><pub-id pub-id-type="pmid">27384081</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00089"><label>26.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Antibodies Online</collab>
</person-group><article-title>Datasheet for ABIN997000, Syphilis IgM Antibody ELISA Kit</article-title><comment>Available online: <ext-link xlink:href="https://pdf.antibodies-online.com/productsheets/ABIN997000.pdf" ext-link-type="uri">https://pdf.antibodies-online.com/productsheets/ABIN997000.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-04">(accessed on 4 April 2023)</date-in-citation></element-citation></ref><ref id="B27-vetsci-12-00089"><label>27.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>DRG Instruments GmbH</collab>
</person-group><article-title>Instructions for Use. Rubella IgM ELISA (Ref: EIA-3511)</article-title><comment>Available online: <ext-link xlink:href="https://www.drg-diagnostics.de/files/eia-3511_ifu--rubella-igm_2021-04-15_ce_endeit.pdf" ext-link-type="uri">https://www.drg-diagnostics.de/files/eia-3511_ifu--rubella-igm_2021-04-15_ce_endeit.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B28-vetsci-12-00089"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazzu-Nascimento</surname><given-names>T.</given-names></name>
<name><surname>Morbioli</surname><given-names>G.G.</given-names></name>
<name><surname>Milan</surname><given-names>L.A.</given-names></name>
<name><surname>Silva</surname><given-names>D.F.</given-names></name>
<name><surname>Donofrio</surname><given-names>F.C.</given-names></name>
<name><surname>Mestrinerg</surname><given-names>C.A.</given-names></name>
<name><surname>Carrilho</surname><given-names>E.</given-names></name>
</person-group><article-title>Improved assessment of accuracy and performance indicators in paper-based ELISA</article-title><source>Anal. Methods</source><year>2017</year><volume>9</volume><fpage>2644</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.1039/C7AY00505A</pub-id></element-citation></ref><ref id="B29-vetsci-12-00089"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Covaleda</surname><given-names>L.M.</given-names></name>
<name><surname>Martins</surname><given-names>M.</given-names></name>
<name><surname>Reinhart</surname><given-names>J.M.</given-names></name>
<name><surname>Sullivan</surname><given-names>D.R.</given-names></name>
<name><surname>Diel</surname><given-names>D.G.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure in animals</article-title><source>mSphere</source><year>2023</year><volume>8</volume><fpage>e0006723</fpage><pub-id pub-id-type="doi">10.1128/msphere.00067-23</pub-id><pub-id pub-id-type="pmid">37409816</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00089"><label>30.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Conrad</surname><given-names>B.</given-names></name>
</person-group><article-title>%CV in ELISA: How to Reduce Them and Why They&#x02019;re Important. Enzo Biochem Inc</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.enzo.com/note/cv-in-elisa-how-to-reduce-them-and-why-theyre-important/" ext-link-type="uri">https://www.enzo.com/note/cv-in-elisa-how-to-reduce-them-and-why-theyre-important/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-18">(accessed on 18 January 2023)</date-in-citation></element-citation></ref><ref id="B31-vetsci-12-00089"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>G.F.</given-names></name>
<name><surname>Lopes-Bezerra</surname><given-names>L.M.</given-names></name>
<name><surname>Bernardes-Engemann</surname><given-names>A.R.</given-names></name>
<name><surname>Schubach</surname><given-names>T.M.P.</given-names></name>
<name><surname>Dias</surname><given-names>M.A.G.</given-names></name>
<name><surname>Pereira</surname><given-names>S.A.</given-names></name>
<name><surname>de Camargo</surname><given-names>Z.P.</given-names></name>
</person-group><article-title>Serodiagnosis of sporotrichosis infection in cats by enzyme-linked immunosorbent assay using a specific antigen, SsCBF, and crude exoantigens</article-title><source>Vet. Microbiol.</source><year>2011</year><volume>147</volume><fpage>445</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2010.07.007</pub-id><pub-id pub-id-type="pmid">20708355</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00089"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Green</surname><given-names>D.J.</given-names></name>
<name><surname>Litt</surname><given-names>G.J.</given-names></name>
<name><surname>Laugharn</surname><given-names>J.A.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Use of high pressure to accelerate antibody: Antigen binding kinetics demonstrated in an HIV-1 p24: Anti-HIV-1 p24 assay</article-title><source>Clin. Chem.</source><year>1998</year><volume>44</volume><fpage>341</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1093/clinchem/44.2.341</pub-id><pub-id pub-id-type="pmid">9474034</pub-id>
</element-citation></ref><ref id="B33-vetsci-12-00089"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jia</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>H.</given-names></name>
<name><surname>Bin</surname><given-names>P.</given-names></name>
<name><surname>Niu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhong</surname><given-names>L.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Myelin protein zero and its antibody in serum as biomarkers of n-hexane-induced peripheral neuropathy and neurotoxicity effects</article-title><source>Chin. Med. J.</source><year>2014</year><volume>127</volume><fpage>1536</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">24762602</pub-id>
</element-citation></ref><ref id="B34-vetsci-12-00089"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liew</surname><given-names>O.W.</given-names></name>
<name><surname>Ling</surname><given-names>S.S.M.</given-names></name>
<name><surname>Lilyanna</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Chong</surname><given-names>J.P.C.</given-names></name>
<name><surname>Ng</surname><given-names>Y.X.</given-names></name>
<name><surname>Lim</surname><given-names>A.E.S.</given-names></name>
<name><surname>Leong</surname><given-names>E.R.Y.</given-names></name>
<name><surname>Lin</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation</article-title><source>Commun. Biol.</source><year>2021</year><volume>4</volume><fpage>531</fpage><pub-id pub-id-type="doi">10.1038/s42003-021-02091-4</pub-id><pub-id pub-id-type="pmid">33947931</pub-id>
</element-citation></ref><ref id="B35-vetsci-12-00089"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Overwijk</surname><given-names>W.W.</given-names></name>
<name><surname>de Visser</surname><given-names>K.E.</given-names></name>
<name><surname>Tirion</surname><given-names>F.H.</given-names></name>
<name><surname>de Jong</surname><given-names>L.A.</given-names></name>
<name><surname>Pols</surname><given-names>T.W.H.</given-names></name>
<name><surname>van der Velden</surname><given-names>Y.U.</given-names></name>
<name><surname>van den Boorn</surname><given-names>J.G.</given-names></name>
<name><surname>Keller</surname><given-names>A.M.</given-names></name>
<name><surname>Buurman</surname><given-names>W.A.</given-names></name>
<name><surname>Theoret</surname><given-names>M.R.</given-names></name>
<etal/>
</person-group><article-title>Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant</article-title><source>J. Immunol.</source><year>2006</year><volume>176</volume><fpage>5213</fpage><lpage>5222</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.9.5213</pub-id><pub-id pub-id-type="pmid">16621986</pub-id>
</element-citation></ref><ref id="B36-vetsci-12-00089"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deutschmann</surname><given-names>C.</given-names></name>
<name><surname>Roggenbuck</surname><given-names>D.</given-names></name>
<name><surname>Schierack</surname><given-names>P.</given-names></name>
<name><surname>Rodiger</surname><given-names>S.</given-names></name>
</person-group><article-title>Autoantibody testing by enzyme-linked immunosorbent assay-a case in which the solid phase decides on success and failure</article-title><source>Helicon</source><year>2020</year><volume>6</volume><fpage>e03270</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e03270</pub-id></element-citation></ref><ref id="B37-vetsci-12-00089"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rusanen</surname><given-names>J.</given-names></name>
<name><surname>Kareinen</surname><given-names>L.</given-names></name>
<name><surname>Levanov</surname><given-names>L.</given-names></name>
<name><surname>Mero</surname><given-names>S.</given-names></name>
<name><surname>Pakkanen</surname><given-names>S.H.</given-names></name>
<name><surname>Kantele</surname><given-names>A.</given-names></name>
<name><surname>Amanat</surname><given-names>F.</given-names></name>
<name><surname>Krammer</surname><given-names>F.</given-names></name>
<name><surname>Hedman</surname><given-names>K.</given-names></name>
<name><surname>Vapalahti</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>143</elocation-id><pub-id pub-id-type="doi">10.3390/v13020143</pub-id><pub-id pub-id-type="pmid">33498157</pub-id>
</element-citation></ref><ref id="B38-vetsci-12-00089"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piepers</surname><given-names>S.</given-names></name>
<name><surname>Jansen</surname><given-names>M.D.</given-names></name>
<name><surname>Cats</surname><given-names>E.A.</given-names></name>
<name><surname>van Sorge</surname><given-names>N.M.</given-names></name>
<name><surname>van den Berg</surname><given-names>L.H.</given-names></name>
<name><surname>van der Pol</surname><given-names>W.L.</given-names></name>
</person-group><article-title>VIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN</article-title><source>J. Neuroimmunol.</source><year>2010</year><volume>229</volume><fpage>256</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.08.023</pub-id><pub-id pub-id-type="pmid">20920831</pub-id>
</element-citation></ref><ref id="B39-vetsci-12-00089"><label>39.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>IDEXX Laboratories</collab>
</person-group><article-title>IDEXX Snap&#x02014;Test Rapidi per Diagnosi in Clinica. Facili, Veloci, Accurati</article-title><year>2017</year><comment>Available online: <ext-link xlink:href="https://www.idexx.it/files/nuova-brochure-test-rapidi-idexx-it.pdf" ext-link-type="uri">https://www.idexx.it/files/nuova-brochure-test-rapidi-idexx-it.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-24">(accessed on 24 January 2023)</date-in-citation></element-citation></ref><ref id="B40-vetsci-12-00089"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westman</surname><given-names>M.E.</given-names></name>
<name><surname>Malik</surname><given-names>R.</given-names></name>
<name><surname>Hall</surname><given-names>E.</given-names></name>
<name><surname>Sheehy</surname><given-names>P.A.</given-names></name>
<name><surname>Norris</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Determining the feline immunodeficiency virus (FIV) status of FIV-vaccinated cats using point-of-care antibody kits</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2015</year><volume>42</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2015.07.004</pub-id><pub-id pub-id-type="pmid">26459979</pub-id>
</element-citation></ref><ref id="B41-vetsci-12-00089"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westman</surname><given-names>M.E.</given-names></name>
<name><surname>Malik</surname><given-names>R.</given-names></name>
<name><surname>Hall</surname><given-names>E.</given-names></name>
<name><surname>Harris</surname><given-names>M.</given-names></name>
<name><surname>Hosie</surname><given-names>M.J.</given-names></name>
<name><surname>Norris</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Duration of antibody response following vaccination against feline immunodeficiency virus</article-title><source>J. Feline Med. Surg.</source><year>2017</year><volume>19</volume><fpage>1055</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1177/1098612X16673292</pub-id><pub-id pub-id-type="pmid">27770018</pub-id>
</element-citation></ref><ref id="B42-vetsci-12-00089"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Davenport</surname><given-names>K.A.</given-names></name>
<name><surname>Schooley</surname><given-names>E.</given-names></name>
<name><surname>Ruggiero</surname><given-names>A.</given-names></name>
<name><surname>Nassar</surname><given-names>S.</given-names></name>
<name><surname>Buch</surname><given-names>J.</given-names></name>
<name><surname>Chandrashekar</surname><given-names>R.</given-names></name>
</person-group><article-title>Diagnostic Accuracy of a Point-of-Care Immunoassay for Feline Immunodeficiency Virus Antibodies, Feline Leukemia Virus Antigen, and <italic toggle="yes">Dirofilaria immitis</italic> Antigen</article-title><source>Viruses</source><year>2013</year><volume>15</volume><elocation-id>2117</elocation-id><pub-id pub-id-type="doi">10.3390/v15102117</pub-id></element-citation></ref><ref id="B43-vetsci-12-00089"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartmann</surname><given-names>K.</given-names></name>
<name><surname>Griessmayr</surname><given-names>P.</given-names></name>
<name><surname>Schulz</surname><given-names>B.</given-names></name>
<name><surname>Greene</surname><given-names>C.E.</given-names></name>
<name><surname>Vidyashankar</surname><given-names>A.N.</given-names></name>
<name><surname>Jarrett</surname><given-names>O.</given-names></name>
<name><surname>Egberink</surname><given-names>H.F.</given-names></name>
</person-group><article-title>Quality of different in-clinic test systems for feline immunodeficiency virus and feline leukaemia virus infection</article-title><source>J. Feline Med. Surg.</source><year>2007</year><volume>9</volume><fpage>439</fpage><pub-id pub-id-type="doi">10.1016/j.jfms.2007.04.003</pub-id><pub-id pub-id-type="pmid">17604205</pub-id>
</element-citation></ref><ref id="B44-vetsci-12-00089"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riondato</surname><given-names>F.</given-names></name>
<name><surname>Guglielmino</surname><given-names>R.</given-names></name>
<name><surname>Miniscalco</surname><given-names>B.</given-names></name>
<name><surname>Borrelli</surname><given-names>A.</given-names></name>
<name><surname>Tarducci</surname><given-names>A.</given-names></name>
<name><surname>Gomes-Keller</surname><given-names>M.A.</given-names></name>
<name><surname>Lutz</surname><given-names>H.</given-names></name>
</person-group><article-title>Validazione del test Rapido &#x0201c;Snap Combo Plus&#x0201d; (IDEXX) e correlazione con Western Blotting (WB) e Polymerase Chain Reaction (PCR) nella diagnosi di infezione da FIV</article-title><source>Veterinaria</source><year>2005</year><volume>19</volume><fpage>31</fpage><lpage>36</lpage></element-citation></ref><ref id="B45-vetsci-12-00089"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moskaluk</surname><given-names>A.</given-names></name>
<name><surname>Nehring</surname><given-names>M.</given-names></name>
<name><surname>VandeWoude</surname><given-names>S.</given-names></name>
</person-group><article-title>Serum Samples from Co-Infected and Domestic Cat Field Isolates Nonspecifically Bind FIV and Other Antigens in Enzyme-Linked Immunosorbent Assays</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>665</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10060665</pub-id><pub-id pub-id-type="pmid">34071706</pub-id>
</element-citation></ref><ref id="B46-vetsci-12-00089"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Wood</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Cytokines, Antibodies and Plasma Viremia of Cats Infected with Feline Immunodeficiency Virus. UMI Number:3565580</article-title><source>Doctoral Thesis</source><publisher-name>Colorado State University, Department of Microbiology, Immunology and Pathology</publisher-name><publisher-loc>Fort Collins, CO, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B47-vetsci-12-00089"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sprague</surname><given-names>W.S.</given-names></name>
<name><surname>Troyer</surname><given-names>R.M.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Wood</surname><given-names>B.A.</given-names></name>
<name><surname>Macmillan</surname><given-names>M.</given-names></name>
<name><surname>Carver</surname><given-names>S.</given-names></name>
<name><surname>VandeWoude</surname><given-names>S.</given-names></name>
</person-group><article-title>Prior Puma Lentivirus Infection Modifies Early Immune Responses and Attenuates Feline Immunodeficiency Virus Infection in Cats</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.3390/v10040210</pub-id><pub-id pub-id-type="pmid">29677149</pub-id>
</element-citation></ref><ref id="B48-vetsci-12-00089"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ostrowski</surname><given-names>S.</given-names></name>
<name><surname>Van Vuuren</surname><given-names>M.</given-names></name>
<name><surname>Lenain</surname><given-names>D.M.</given-names></name>
<name><surname>Durand</surname><given-names>A.</given-names></name>
</person-group><article-title>A Serologic Survey of Wild Felids from Central West Saudi Arabia</article-title><source>J. Wildl. Dis.</source><year>2003</year><volume>39</volume><fpage>696</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.7589/0090-3558-39.3.696</pub-id><pub-id pub-id-type="pmid">14567233</pub-id>
</element-citation></ref><ref id="B49-vetsci-12-00089"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bienzle</surname><given-names>D.</given-names></name>
<name><surname>Reggeti</surname><given-names>F.</given-names></name>
<name><surname>Wen</surname><given-names>X.</given-names></name>
<name><surname>Little</surname><given-names>S.</given-names></name>
<name><surname>Hobson</surname><given-names>J.</given-names></name>
<name><surname>Kruth</surname><given-names>S.</given-names></name>
</person-group><article-title>The variability of serological and molecular diagnosis of feline immunodeficiency virus infection</article-title><source>Can. Vet. J.</source><year>2004</year><volume>45</volume><fpage>753</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">15510684</pub-id>
</element-citation></ref><ref id="B50-vetsci-12-00089"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donato</surname><given-names>G.</given-names></name>
<name><surname>Caspanello</surname><given-names>T.</given-names></name>
<name><surname>Capr&#x000ec;</surname><given-names>A.</given-names></name>
<name><surname>De Majo</surname><given-names>M.</given-names></name>
<name><surname>Iannelli</surname><given-names>N.M.</given-names></name>
<name><surname>Rosace</surname><given-names>F.</given-names></name>
<name><surname>Bruno</surname><given-names>F.</given-names></name>
<name><surname>Castelli</surname><given-names>G.</given-names></name>
<name><surname>Pennisi</surname><given-names>M.G.</given-names></name>
<name><surname>Masucci</surname><given-names>M.</given-names></name>
</person-group><article-title>The erythrocyte sedimentation rate and other markers of inflammation in cats tested for <italic toggle="yes">Leishmania infantum</italic> and feline immunodeficiency virus antibodies</article-title><source>Parasites Vectors</source><year>2024</year><volume>17</volume><fpage>324</fpage><pub-id pub-id-type="doi">10.1186/s13071-024-06396-1</pub-id><pub-id pub-id-type="pmid">39080701</pub-id>
</element-citation></ref><ref id="B51-vetsci-12-00089"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>C.L.</given-names></name>
<name><surname>Britton</surname><given-names>Z.T.</given-names></name>
<name><surname>Robinson</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Recombinant protein expression and purification: A comprehensive review of affinity tags and microbial applications</article-title><source>Biotechnol. J.</source><year>2012</year><volume>7</volume><fpage>620</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1002/biot.201100155</pub-id><pub-id pub-id-type="pmid">22442034</pub-id>
</element-citation></ref><ref id="B52-vetsci-12-00089"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Debeljak</surname><given-names>N.</given-names></name>
<name><surname>Feldman</surname><given-names>L.</given-names></name>
<name><surname>Davis</surname><given-names>K.L.</given-names></name>
<name><surname>Komel</surname><given-names>R.</given-names></name>
<name><surname>Sytkowski</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Variability in the immunodetection of His-tagged recombinant proteins</article-title><source>Anal. Biochem.</source><year>2006</year><volume>359</volume><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2006.09.017</pub-id><pub-id pub-id-type="pmid">17081490</pub-id>
</element-citation></ref><ref id="B53-vetsci-12-00089"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>R.</given-names></name>
<name><surname>Yi</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Han</surname><given-names>Q.</given-names></name>
<name><surname>Xia</surname><given-names>X.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Development of alkaline phosphatase-scFv and its use for one-step enzyme-linked immunosorbent assay for His-tagged protein detection</article-title><source>Open Life Sci.</source><year>2022</year><volume>17</volume><fpage>1505</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1515/biol-2022-0521</pub-id><pub-id pub-id-type="pmid">36448055</pub-id>
</element-citation></ref><ref id="B54-vetsci-12-00089"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lindner</surname><given-names>P.</given-names></name>
<name><surname>Bauer</surname><given-names>K.</given-names></name>
<name><surname>Krebber</surname><given-names>A.</given-names></name>
<name><surname>Nieba</surname><given-names>L.</given-names></name>
<name><surname>Kremmer</surname><given-names>E.</given-names></name>
<name><surname>Krebber</surname><given-names>C.</given-names></name>
<name><surname>Honegger</surname><given-names>A.</given-names></name>
<name><surname>Klinger</surname><given-names>B.</given-names></name>
<name><surname>Mocikat</surname><given-names>R.</given-names></name>
<name><surname>Pl&#x000fc;ckthun</surname><given-names>A.</given-names></name>
</person-group><article-title>Specific Detection of His-Tagged Proteins with Recombinant Anti-His Tag scFv-Phosphatase or scFv-Phage Fusions</article-title><source>BioTechniques</source><year>1997</year><volume>22</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.2144/97221rr01</pub-id><pub-id pub-id-type="pmid">8994661</pub-id>
</element-citation></ref><ref id="B55-vetsci-12-00089"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zentgraf</surname><given-names>H.</given-names></name>
<name><surname>Frey</surname><given-names>M.</given-names></name>
<name><surname>Schwinn</surname><given-names>S.</given-names></name>
<name><surname>Tessmer</surname><given-names>C.</given-names></name>
<name><surname>Willemann</surname><given-names>B.</given-names></name>
<name><surname>Samstag</surname><given-names>Y.</given-names></name>
<name><surname>Velhagen</surname><given-names>I.</given-names></name>
</person-group><article-title>Detection of histidine-tagged fusion proteins by using a high-specific mouse monoclonal anti-histidine tag antibody</article-title><source>Nucleic Acids Res.</source><year>1995</year><volume>23</volume><fpage>3347</fpage><lpage>3348</lpage><pub-id pub-id-type="doi">10.1093/nar/23.16.3347</pub-id><pub-id pub-id-type="pmid">7667114</pub-id>
</element-citation></ref><ref id="B56-vetsci-12-00089"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raditic</surname><given-names>D.M.</given-names></name>
<name><surname>Remillard</surname><given-names>R.L.</given-names></name>
<name><surname>Tater</surname><given-names>K.C.</given-names></name>
</person-group><article-title>ELISA testing for common food antigens in four dry dog foods used in dietary elimination trials</article-title><source>J. Anim. Physiol. Anim. Nutr.</source><year>2011</year><volume>95</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0396.2010.01016.x</pub-id></element-citation></ref><ref id="B57-vetsci-12-00089"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sirikajornpan</surname><given-names>K.</given-names></name>
<name><surname>Suntarattiwong</surname><given-names>P.</given-names></name>
<name><surname>Suwanpakdee</surname><given-names>D.</given-names></name>
<name><surname>Tabprasit</surname><given-names>S.</given-names></name>
<name><surname>Buddhari</surname><given-names>D.</given-names></name>
<name><surname>Thaisomboonsuk</surname><given-names>B.</given-names></name>
<name><surname>Klungthong</surname><given-names>C.</given-names></name>
<name><surname>Poolpanichupatam</surname><given-names>Y.</given-names></name>
<name><surname>Buathong</surname><given-names>R.</given-names></name>
<name><surname>Srikiatkhachorn</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Standardization and Evaluation of an Anti-ZIKV IgM ELISA Assay for the Serological Diagnosis of Zika Virus Infection</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2021</year><volume>105</volume><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.21-0163</pub-id><pub-id pub-id-type="pmid">34339380</pub-id>
</element-citation></ref><ref id="B58-vetsci-12-00089"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Valero</surname><given-names>M.A.</given-names></name>
<name><surname>Periago</surname><given-names>M.V.</given-names></name>
<name><surname>P&#x000e9;rez-Crespo</surname><given-names>I.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>E.</given-names></name>
<name><surname>Perteguer</surname><given-names>M.J.</given-names></name>
<name><surname>G&#x000e1;rate</surname><given-names>T.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Barber&#x000e1;</surname><given-names>E.M.</given-names></name>
<name><surname>Mas-Coma</surname><given-names>S.</given-names></name>
</person-group><article-title>Assessing the validity of an ELISA test for the serological diagnosis of human fascioliasis in different epidemiological situations</article-title><source>Trop. Med. Int. Health</source><year>2012</year><volume>17</volume><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3156.2012.02964.x</pub-id><pub-id pub-id-type="pmid">22413850</pub-id>
</element-citation></ref><ref id="B59-vetsci-12-00089"><label>59.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>European Monoclonal Antibodies Network (EuroMAbNet)</collab>
</person-group><article-title>ELISA Protocol</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.euromabnet.com/protocols/elisa.php" ext-link-type="uri">https://www.euromabnet.com/protocols/elisa.php</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-23">(accessed on 23 February 2023)</date-in-citation></element-citation></ref><ref id="B60-vetsci-12-00089"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hagler</surname><given-names>J.R.</given-names></name>
<name><surname>Naranjo</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Determining the frequency of heteropteran predation on sweetpotato whitefly and pink bollworm using multiple ELISAs</article-title><source>Entomol. Exp. Appl.</source><year>1994</year><volume>72</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/j.1570-7458.1994.tb01802.x</pub-id></element-citation></ref><ref id="B61-vetsci-12-00089"><label>61.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>ImmunoReagents Inc</collab>
</person-group><article-title>A General Protocol on How to Conduct an ELISA Assay. 2012&#x02013;2024</article-title><comment>Available online: <ext-link xlink:href="https://www.immunoreagents.com/protocols/view/2" ext-link-type="uri">https://www.immunoreagents.com/protocols/view/2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-28">(accessed on 28 February 2023)</date-in-citation></element-citation></ref><ref id="B62-vetsci-12-00089"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niedrig</surname><given-names>M.</given-names></name>
<name><surname>Lademann</surname><given-names>M.</given-names></name>
<name><surname>Emmerich</surname><given-names>P.</given-names></name>
<name><surname>Lafrenz</surname><given-names>M.</given-names></name>
</person-group><article-title>Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: Neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA</article-title><source>Trop. Med. Int. Health</source><year>1999</year><volume>4</volume><fpage>867</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3156.1999.00496.x</pub-id><pub-id pub-id-type="pmid">10632996</pub-id>
</element-citation></ref><ref id="B63-vetsci-12-00089"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Kuang</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
</person-group><article-title>Development of a Monoclonal Antibody-Based Sandwich ELISA for Peanut Allergen Ara h 1 in Food</article-title><source>Int. J. Environ. Res.</source><year>2013</year><volume>10</volume><fpage>2897</fpage><lpage>2905</lpage><pub-id pub-id-type="doi">10.3390/ijerph10072897</pub-id><pub-id pub-id-type="pmid">23880725</pub-id>
</element-citation></ref><ref id="B64-vetsci-12-00089"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Priolo</surname><given-names>V.</given-names></name>
<name><surname>Masucci</surname><given-names>M.</given-names></name>
<name><surname>Donato</surname><given-names>G.</given-names></name>
<name><surname>Solano-Gallego</surname><given-names>L.</given-names></name>
<name><surname>Mart&#x000ed;nez-Orellana</surname><given-names>P.</given-names></name>
<name><surname>Persichetti</surname><given-names>M.F.</given-names></name>
<name><surname>Raya-Berm&#x000fa;dez</surname><given-names>A.</given-names></name>
<name><surname>Vitale</surname><given-names>F.</given-names></name>
<name><surname>Pennisi</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Association between feline immunodeficiency virus and <italic toggle="yes">Leishmania infantum</italic> infections in cats: A retrospective matched case-control study</article-title><source>Parasites Vectors</source><year>2022</year><volume>15</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s13071-022-05230-w</pub-id><pub-id pub-id-type="pmid">35534884</pub-id>
</element-citation></ref><ref id="B65-vetsci-12-00089"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roelke</surname><given-names>M.E.</given-names></name>
<name><surname>Johnson</surname><given-names>W.E.</given-names></name>
<name><surname>Mill&#x000e1;n</surname><given-names>J.</given-names></name>
<name><surname>Palomares</surname><given-names>F.</given-names></name>
<name><surname>Revilla</surname><given-names>E.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name>
<name><surname>Calzada</surname><given-names>J.</given-names></name>
<name><surname>Ferreras</surname><given-names>P.</given-names></name>
<name><surname>Le&#x000f3;n-Vizca&#x000ed;no</surname><given-names>L.</given-names></name>
<name><surname>Delibes</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Exposure to disease agents in the endangered Iberian lynx (<italic toggle="yes">Lynx pardinus</italic>)</article-title><source>Eur. J. Wildl. Res.</source><year>2008</year><volume>54</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s10344-007-0122-2</pub-id><pub-id pub-id-type="pmid">32214935</pub-id>
</element-citation></ref><ref id="B66-vetsci-12-00089"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roels</surname><given-names>E.</given-names></name>
<name><surname>Debie</surname><given-names>C.</given-names></name>
<name><surname>Giraud</surname><given-names>S.</given-names></name>
<name><surname>Ferreira</surname><given-names>R.</given-names></name>
<name><surname>Gommeren</surname><given-names>K.</given-names></name>
</person-group><article-title>Prevalence of Hemoplasma spp. positivity in potential feline blood donors and study of the association with selected clinical variables</article-title><source>J. Vet. Intern. Med.</source><year>2024</year><volume>38</volume><fpage>2151</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1111/jvim.17119</pub-id><pub-id pub-id-type="pmid">38803041</pub-id>
</element-citation></ref><ref id="B67-vetsci-12-00089"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sch&#x000e4;fer</surname><given-names>I.</given-names></name>
<name><surname>Kohn</surname><given-names>B.</given-names></name>
<name><surname>Nijhof</surname><given-names>A.M.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>E.</given-names></name>
</person-group><article-title>Molecular detection of Hepatozoon species infections in domestic cats living in Germany</article-title><source>J. Feline Med. Surg.</source><year>2022</year><volume>24</volume><fpage>994</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1177/1098612X211055680</pub-id><pub-id pub-id-type="pmid">34781752</pub-id>
</element-citation></ref><ref id="B68-vetsci-12-00089"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sch&#x000e4;fer</surname><given-names>I.</given-names></name>
<name><surname>Schmidt</surname><given-names>A.</given-names></name>
<name><surname>Gr&#x000e4;&#x000df;er</surname><given-names>F.</given-names></name>
<name><surname>Schieszler</surname><given-names>A.</given-names></name>
<name><surname>Aupperle-Lellbach</surname><given-names>H.</given-names></name>
<name><surname>Loesenbeck</surname><given-names>G.</given-names></name>
<name><surname>Gentil</surname><given-names>M.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>E.</given-names></name>
<name><surname>Naucke</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Feline leishmaniosis with focus on ocular manifestation: A case report</article-title><source>Parasites Vectors</source><year>2023</year><volume>16</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1186/s13071-023-05741-0</pub-id><pub-id pub-id-type="pmid">37173777</pub-id>
</element-citation></ref><ref id="B69-vetsci-12-00089"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campa</surname><given-names>C.</given-names></name>
<name><surname>Pronce</surname><given-names>T.</given-names></name>
<name><surname>Paludi</surname><given-names>M.</given-names></name>
<name><surname>Weusten</surname><given-names>J.</given-names></name>
<name><surname>Conway</surname><given-names>L.</given-names></name>
<name><surname>Savery</surname><given-names>J.</given-names></name>
<name><surname>Richards</surname><given-names>C.</given-names></name>
<name><surname>Cl&#x000e9;net</surname><given-names>D.</given-names></name>
</person-group><article-title>Use of Stability Modeling to Support Accelerated Vaccine Development and Supply</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1114</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9101114</pub-id><pub-id pub-id-type="pmid">34696222</pub-id>
</element-citation></ref><ref id="B70-vetsci-12-00089"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cannell</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Fundamentals of stability testing</article-title><source>Int. J. Cosmet. Sci.</source><year>1985</year><volume>7</volume><fpage>291</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1111/j.1467-2494.1985.tb00423.x</pub-id><pub-id pub-id-type="pmid">19460040</pub-id>
</element-citation></ref><ref id="B71-vetsci-12-00089"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bajaj</surname><given-names>S.</given-names></name>
<name><surname>Singla</surname><given-names>D.</given-names></name>
<name><surname>Sakhuja</surname><given-names>N.</given-names></name>
</person-group><article-title>Stability Testing of Pharmaceutical Products</article-title><source>J. Appl. Pharm. Sci.</source><year>2012</year><volume>2</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.7324/JAPS.2012.2322</pub-id></element-citation></ref><ref id="B72-vetsci-12-00089"><label>72.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mechkovski</surname><given-names>A.</given-names></name>
</person-group><source>WHO Guidelines on Stability Testing of Pharmaceutical Products Containing Well-Established Drug Substances in Conventional Dosage Forms</source><publisher-name>World Health Organization (WHO)</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1994</year><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="B73-vetsci-12-00089"><label>73.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Committee for Veterinary Medicinal Products (CVMP)</collab>
</person-group><source>Guideline on Stability Testing for Applications for Variations to a Marketing Authorisation for Veterinary Medicinal Product (EMA/CVMP/QWP/515653/2023)</source><publisher-name>European Medicine Agency (EMA)</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2024</year><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="B74-vetsci-12-00089"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Gonz&#x000e1;lez</surname><given-names>O.</given-names></name>
<name><surname>Ramirez</surname><given-names>I.O.</given-names></name>
<name><surname>Ramirez</surname><given-names>B.I.</given-names></name>
<name><surname>O&#x02019;Connell</surname><given-names>P.</given-names></name>
<name><surname>Ballesteros</surname><given-names>M.P.</given-names></name>
<name><surname>Torrado</surname><given-names>J.J.</given-names></name>
<name><surname>Serrano</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Drug Stability: ICH versus Accelerated Predictive Stability Studies</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2324</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14112324</pub-id><pub-id pub-id-type="pmid">36365143</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00089-f001"><label>Figure 1</label><caption><p>Results of SNAP FIV/FeLV Combo (IDEXX) on eight negative samples with higher OD values in ELISA. Samples: n. 53 (code: 61), n. 54 (code: 108), n. 55 (code: 109), n. 56 (code: 94), n. 57 (code: 110), n. 58 (Pau), n.59 (Venuta), n. 60 (Milani).</p></caption><graphic xlink:href="vetsci-12-00089-g001" position="float"/></fig><fig position="float" id="vetsci-12-00089-f002"><label>Figure 2</label><caption><p>Graph showing the OD values (black dots) of the data obtained during validation. The red line indicates the OD 0.300 as the cut-off level separating negative and positive samples.</p></caption><graphic xlink:href="vetsci-12-00089-g002" position="float"/></fig><fig position="float" id="vetsci-12-00089-f003"><label>Figure 3</label><caption><p>Methods for cut-off determination. Cut-off was determined by evaluating (<bold>a</bold>) sensibility and specificity parameters; (<bold>b</bold>) ROC curve; and (<bold>c</bold>) Youden&#x02019;s index. N. Cut-off: cut-off number.</p></caption><graphic xlink:href="vetsci-12-00089-g003" position="float"/></fig><fig position="float" id="vetsci-12-00089-f004"><label>Figure 4</label><caption><p>Comparative study of FIVCHECK Ab ELISA (Agrolabo), INgezim FIV ELISA (Gold Standard Diagnostics), and VetLine FIV (NovaTec). Statistical difference was assessed by <italic toggle="yes">t</italic>-test and was marked with an asterisk (<italic toggle="yes">p</italic>-value &#x0003c; 0.05). On positive samples, the difference between means OD was statistically significant between FIVCHECK Ab ELISA and both INgezim FIV and VetLine FIV. On negative ones, the difference between means OD was statistically significant between FIVCHECK Ab ELISA and VetLine FIV. OD: Optical density (450 nm).</p></caption><graphic xlink:href="vetsci-12-00089-g004" position="float"/></fig><table-wrap position="float" id="vetsci-12-00089-t001"><object-id pub-id-type="pii">vetsci-12-00089-t001_Table 1</object-id><label>Table 1</label><caption><p>ELISA preliminary assays on PolySorp Nunc and Costar microplates. Test ELISA on PolySorp Nunc and Costar High Binding microplates blocked with Blocking Buffer 1 and Buffer 2. Coating: 0, 0.25, 0.5, 1 and 2 &#x000b5;g/mL FIV recombinant antigen. Samples: 1 positive and 1 negative (dilution 1:100). Conjugate was tested from 1:2000 to 1:128,000.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin" colspan="1">Samples</th><th rowspan="3" align="center" valign="middle" style="border-top:solid thin" colspan="1">Conjugate</th><th colspan="10" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PolySorp Nunc Plate</th><th colspan="10" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Costar High Binding</th></tr><tr><th colspan="5" align="center" valign="middle" rowspan="1">Blocking Buffer 1</th><th colspan="5" align="center" valign="middle" rowspan="1">Blocking Buffer 2</th><th colspan="5" align="center" valign="middle" rowspan="1">Blocking Buffer 1</th><th colspan="5" align="center" valign="middle" rowspan="1">Blocking Buffer 2</th></tr><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.5</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.25</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.5</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.25</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.5</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.25</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.5</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.25</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1:2000</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.648</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.674</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.609</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.234</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.056</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.624</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.606</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.597</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.529</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.683</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.668</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.642</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.552</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.654</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.674</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.643</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.572</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.077</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:4000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.637</td><td align="center" valign="middle" rowspan="1" colspan="1">2.620</td><td align="center" valign="middle" rowspan="1" colspan="1">2.428</td><td align="center" valign="middle" rowspan="1" colspan="1">1.480</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">2.601</td><td align="center" valign="middle" rowspan="1" colspan="1">2.585</td><td align="center" valign="middle" rowspan="1" colspan="1">2.475</td><td align="center" valign="middle" rowspan="1" colspan="1">2.083</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">2.673</td><td align="center" valign="middle" rowspan="1" colspan="1">2.621</td><td align="center" valign="middle" rowspan="1" colspan="1">2.564</td><td align="center" valign="middle" rowspan="1" colspan="1">2.210</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">2.651</td><td align="center" valign="middle" rowspan="1" colspan="1">2.659</td><td align="center" valign="middle" rowspan="1" colspan="1">2.586</td><td align="center" valign="middle" rowspan="1" colspan="1">2.332</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:8000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.474</td><td align="center" valign="middle" rowspan="1" colspan="1">2.342</td><td align="center" valign="middle" rowspan="1" colspan="1">1.764</td><td align="center" valign="middle" rowspan="1" colspan="1">0.838</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">2.398</td><td align="center" valign="middle" rowspan="1" colspan="1">2.305</td><td align="center" valign="middle" rowspan="1" colspan="1">1.928</td><td align="center" valign="middle" rowspan="1" colspan="1">1.316</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">2.555</td><td align="center" valign="middle" rowspan="1" colspan="1">2.455</td><td align="center" valign="middle" rowspan="1" colspan="1">2.151</td><td align="center" valign="middle" rowspan="1" colspan="1">1.504</td><td align="center" valign="middle" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">2.544</td><td align="center" valign="middle" rowspan="1" colspan="1">2.485</td><td align="center" valign="middle" rowspan="1" colspan="1">2.243</td><td align="center" valign="middle" rowspan="1" colspan="1">1.664</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:16,000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.941</td><td align="center" valign="middle" rowspan="1" colspan="1">1.647</td><td align="center" valign="middle" rowspan="1" colspan="1">1.065</td><td align="center" valign="middle" rowspan="1" colspan="1">0.475</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">1.800</td><td align="center" valign="middle" rowspan="1" colspan="1">1.628</td><td align="center" valign="middle" rowspan="1" colspan="1">1.191</td><td align="center" valign="middle" rowspan="1" colspan="1">0.717</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">2.096</td><td align="center" valign="middle" rowspan="1" colspan="1">1.903</td><td align="center" valign="middle" rowspan="1" colspan="1">1.448</td><td align="center" valign="middle" rowspan="1" colspan="1">0.866</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">2.112</td><td align="center" valign="middle" rowspan="1" colspan="1">1.915</td><td align="center" valign="middle" rowspan="1" colspan="1">1.517</td><td align="center" valign="middle" rowspan="1" colspan="1">0.987</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:32,000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.159</td><td align="center" valign="middle" rowspan="1" colspan="1">0.928</td><td align="center" valign="middle" rowspan="1" colspan="1">0.580</td><td align="center" valign="middle" rowspan="1" colspan="1">0.249</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">1.059</td><td align="center" valign="middle" rowspan="1" colspan="1">0.919</td><td align="center" valign="middle" rowspan="1" colspan="1">0.681</td><td align="center" valign="middle" rowspan="1" colspan="1">0.404</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">1.327</td><td align="center" valign="middle" rowspan="1" colspan="1">1.129</td><td align="center" valign="middle" rowspan="1" colspan="1">0.818</td><td align="center" valign="middle" rowspan="1" colspan="1">0.441</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">1.301</td><td align="center" valign="middle" rowspan="1" colspan="1">1.146</td><td align="center" valign="middle" rowspan="1" colspan="1">0.864</td><td align="center" valign="middle" rowspan="1" colspan="1">0.528</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:64,000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.652</td><td align="center" valign="middle" rowspan="1" colspan="1">0.528</td><td align="center" valign="middle" rowspan="1" colspan="1">0.323</td><td align="center" valign="middle" rowspan="1" colspan="1">0.148</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.635</td><td align="center" valign="middle" rowspan="1" colspan="1">0.569</td><td align="center" valign="middle" rowspan="1" colspan="1">0.406</td><td align="center" valign="middle" rowspan="1" colspan="1">0.238</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">0.775</td><td align="center" valign="middle" rowspan="1" colspan="1">0.662</td><td align="center" valign="middle" rowspan="1" colspan="1">0.466</td><td align="center" valign="middle" rowspan="1" colspan="1">0.256</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">0.743</td><td align="center" valign="middle" rowspan="1" colspan="1">0.648</td><td align="center" valign="middle" rowspan="1" colspan="1">0.487</td><td align="center" valign="middle" rowspan="1" colspan="1">0.299</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:128,000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.339</td><td align="center" valign="middle" rowspan="1" colspan="1">0.273</td><td align="center" valign="middle" rowspan="1" colspan="1">0.175</td><td align="center" valign="middle" rowspan="1" colspan="1">0.090</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.345</td><td align="center" valign="middle" rowspan="1" colspan="1">0.299</td><td align="center" valign="middle" rowspan="1" colspan="1">0.215</td><td align="center" valign="middle" rowspan="1" colspan="1">0.139</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">0.404</td><td align="center" valign="middle" rowspan="1" colspan="1">0.339</td><td align="center" valign="middle" rowspan="1" colspan="1">0.258</td><td align="center" valign="middle" rowspan="1" colspan="1">0.147</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">0.402</td><td align="center" valign="middle" rowspan="1" colspan="1">0.352</td><td align="center" valign="middle" rowspan="1" colspan="1">0.269</td><td align="center" valign="middle" rowspan="1" colspan="1">0.175</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">1:2000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.233</td><td align="center" valign="middle" rowspan="1" colspan="1">0.133</td><td align="center" valign="middle" rowspan="1" colspan="1">0.087</td><td align="center" valign="middle" rowspan="1" colspan="1">0.068</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td><td align="center" valign="middle" rowspan="1" colspan="1">0.173</td><td align="center" valign="middle" rowspan="1" colspan="1">0.114</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td><td align="center" valign="middle" rowspan="1" colspan="1">0.051</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.260</td><td align="center" valign="middle" rowspan="1" colspan="1">0.137</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" rowspan="1" colspan="1">0.162</td><td align="center" valign="middle" rowspan="1" colspan="1">0.237</td><td align="center" valign="middle" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">0.057</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:4000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.127</td><td align="center" valign="middle" rowspan="1" colspan="1">0.083</td><td align="center" valign="middle" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">0.102</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.146</td><td align="center" valign="middle" rowspan="1" colspan="1">0.090</td><td align="center" valign="middle" rowspan="1" colspan="1">0.071</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">0.138</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:8000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.083</td><td align="center" valign="middle" rowspan="1" colspan="1">0.056</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">0.069</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098</td><td align="center" valign="middle" rowspan="1" colspan="1">0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">0.050</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">0.087</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:16,000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">0.076</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:32,000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">0.051</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.036</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t002"><object-id pub-id-type="pii">vetsci-12-00089-t002_Table 2</object-id><label>Table 2</label><caption><p>ELISA preliminary assays performed on PolySorp Nunc and Costar microplates blocked with Blocking Buffer 1 and Buffer 2. Coating: 0, 0.25, 0.5, 1 and 2 &#x000b5;g/mL FIV recombinant antigen. Samples: 1 positive and 1 negative (dilution 1:100). Statistical analysis was performed by <italic toggle="yes">t</italic>-test considering significant a <italic toggle="yes">p</italic>-value &#x0003c; 0.05 and by calculation of the Cohen&#x02019;s d index (Effect size). Statistically significant data are marked with an asterisk. Cohen&#x02019;s d (Effect size): d = 0.2 small effect, d = 0.5 moderate effect, d = 0.8 great effect.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Antigen (&#x000b5;g/mL)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Plate</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Positive Sample</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Negative Sample</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean OD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effect Size</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean OD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effect Size</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Blocking Buffer 1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.788</td><td align="center" valign="middle" rowspan="1" colspan="1">0.856</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.126</td><td align="center" valign="middle" rowspan="1" colspan="1">0.723</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.693</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.108</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.682</td><td align="center" valign="middle" rowspan="1" colspan="1">0.840</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.080</td><td align="center" valign="middle" rowspan="1" colspan="1">0.686</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.573</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.478</td><td align="center" valign="middle" rowspan="1" colspan="1">0.713</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">0.510</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.278</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.050</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.139</td><td align="center" valign="middle" rowspan="1" colspan="1">0.473</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" rowspan="1" colspan="1">0.290</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">0.788</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.168</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.063</td><td align="center" valign="middle" rowspan="1" colspan="1">0.329</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Blocking Buffer 2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.772</td><td align="center" valign="middle" rowspan="1" colspan="1">0.796</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" rowspan="1" colspan="1">0.468</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.637</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.086</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.697</td><td align="center" valign="middle" rowspan="1" colspan="1">0.796</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">0.939</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.559</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.063</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.516</td><td align="center" valign="middle" rowspan="1" colspan="1">0.820</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.731</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.637</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">1.222</td><td align="center" valign="middle" rowspan="1" colspan="1">0.758</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">0.202</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.061</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">Costar</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1.595</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nunc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t003"><object-id pub-id-type="pii">vetsci-12-00089-t003_Table 3</object-id><label>Table 3</label><caption><p>Results of FIVCHECK Ab ELISA obtained from sample dilution 1:100 or 1:200. ELISA performances were compared against the reference test SNAP FIV/FeLV Combo (IDEXX). Sample dilution 1:100 resulted in ELISA sensitivity of 100% and specificity of 81.3%. Sample dilution 1:200 resulted in ELISA sensitivity of 100% and specificity of 100%. (a) true positives; (b) false positives; (c) false negatives; (d) true negatives.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">Sample Dilution</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">FIVCHECK Ab ELISA (Agrolabo)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">SNAP FIV/FeLV Combo (IDEXX)</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Positive</th><th align="center" valign="middle" rowspan="1" colspan="1">Negative</th><th align="center" valign="middle" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1:100</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">26 (a)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">6 (b)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (c)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (d)</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1:200</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (a)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (b)</td><td align="center" valign="middle" rowspan="1" colspan="1">37</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (c)</td><td align="center" valign="middle" rowspan="1" colspan="1">76 (d)</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t004"><object-id pub-id-type="pii">vetsci-12-00089-t004_Table 4</object-id><label>Table 4</label><caption><p>Evaluation of positive and negative controls in FIVCHECK Ab ELISA. Conjugate antibody was tested at dilutions 1:8000 or 1:15,000. Results are expressed as mean OD &#x000b1; standard deviation. PC1 and PC2: positive controls anti-His HRP antibody; NC: negative control (sample diluent). Negative samples were tested diluted 1:200 with conjugate antibody 1:8000 or 1:15,000. n: number of tests; n.d.: not determined.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Samples</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dilution</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Conjugate</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:8000</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:15,000</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC1</td><td align="center" valign="middle" rowspan="1" colspan="1">1:2000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.642 &#x000b1; 0.008 (n = 2)</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:4000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.319 &#x000b1; 0.004 (n = 2)</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:8000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.987 &#x000b1; 0.009 (n = 2)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.006 &#x000b1; 0.036 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:10,000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.467 &#x000b1; 0.015 (n = 6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.479 &#x000b1; 0.062 (n = 2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:12,000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.248 &#x000b1; 0.041 (n = 4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.293 &#x000b1; 0.010 (n = 2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:16,000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.931 &#x000b1; 0.134 (n = 4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.811 &#x000b1; 0.001 (n = 2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC2</td><td align="center" valign="middle" rowspan="1" colspan="1">1:2000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:4000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:5000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:8000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:10,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:12,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:16,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:20,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;4.000 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:30,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">3.618 &#x000b1; 0.060 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:40,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">3.237 &#x000b1; 0.071 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:50,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">2.762 &#x000b1; 0.049 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1:60,000</td><td align="center" valign="middle" rowspan="1" colspan="1">n.d.</td><td align="center" valign="middle" rowspan="1" colspan="1">2.569 &#x000b1; 0.080 (n = 3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037 &#x000b1; 0.002 (n = 18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035 &#x000b1; 0.003 (n = 18)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative samples</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.108 &#x000b1; 0.078 (n = 76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.076 &#x000b1; 0.051 (n = 77)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t005"><object-id pub-id-type="pii">vetsci-12-00089-t005_Table 5</object-id><label>Table 5</label><caption><p>Validation results of FIVCHECK Ab ELISA (Agrolabo) against the reference test SNAP FIV/FeLV Combo (IDEXX). Total number of samples analyzed: 115. (a) true positives; (b) false positives; (c) false negatives; (d) true negatives. Proportion of agreement (a + d/a + b + c + d): 100%; Cohen&#x02019;s Kappa: 1.000; Sensitivity: 100%; Specificity: 100%.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">FIVCHECK Ab ELISA (Agrolabo)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">SNAP FIV/FeLV Combo (IDEXX)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (a)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (b)</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (c)</td><td align="center" valign="middle" rowspan="1" colspan="1">77 (d)</td><td align="center" valign="middle" rowspan="1" colspan="1">77</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t006"><object-id pub-id-type="pii">vetsci-12-00089-t006_Table 6</object-id><label>Table 6</label><caption><p>Summary of the reproducibility study. For each sample, the overall number of tests (N), the mean OD, standard deviation (SD), %CV, the median, variance, mode, the minimum (Min) and maximum (Max) OD values, and %CV for intra- and inter-assay were reported. PC1: positive control anti-His HRP antibody (1:300); PC2: a positive control anti-His HRP antibody (1:60,000); NC: negative control; sample 121 (negative), sample 3 (positive), sample 7 (positive).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">N</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mean OD</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">SD</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">%CV</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Min OD</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Max OD</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Median</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variance</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mode OD</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Intra-Assay %CV</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Inter-Assay %CV</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Min</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Max</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Min</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Max</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC1</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">2.700</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">1.443</td><td align="center" valign="middle" rowspan="1" colspan="1">2.621</td><td align="center" valign="middle" rowspan="1" colspan="1">2.793</td><td align="center" valign="middle" rowspan="1" colspan="1">2.697</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001490</td><td align="center" valign="middle" rowspan="1" colspan="1">2.706</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td><td align="center" valign="middle" rowspan="1" colspan="1">2.246</td><td align="center" valign="middle" rowspan="1" colspan="1">0.175</td><td align="center" valign="middle" rowspan="1" colspan="1">1.977</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC2</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">3.165</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">1.140</td><td align="center" valign="middle" rowspan="1" colspan="1">3.112</td><td align="center" valign="middle" rowspan="1" colspan="1">3.258</td><td align="center" valign="middle" rowspan="1" colspan="1">3.162</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001280</td><td align="center" valign="middle" rowspan="1" colspan="1">3.169</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">1.836</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">1.019</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">4.579</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">9.959</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">8.081</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 121 (&#x02212;)</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">8.647</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.057</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000016</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">10.607</td><td align="center" valign="middle" rowspan="1" colspan="1">0.760</td><td align="center" valign="middle" rowspan="1" colspan="1">8.772</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 3 (+)</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">1.497</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">2.014</td><td align="center" valign="middle" rowspan="1" colspan="1">1.427</td><td align="center" valign="middle" rowspan="1" colspan="1">1.530</td><td align="center" valign="middle" rowspan="1" colspan="1">1.510</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000893</td><td align="center" valign="middle" rowspan="1" colspan="1">1.520</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">3.235</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td><td align="center" valign="middle" rowspan="1" colspan="1">3.145</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sample 7 (+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.746</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.799</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.808</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.754</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000969</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.742</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.760</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.085</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.698</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t007"><object-id pub-id-type="pii">vetsci-12-00089-t007_Table 7</object-id><label>Table 7</label><caption><p>Analysis of variance by ANOVA on FIVCHECK Ab, INgezim FIV and VetLine FIV ELISA. SS: sum-of-squares terms; df: degrees of freedom; MS: mean squares (variances); F: F value resulted from ANOVA; F crit: critical value F; n: number of samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Samples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Origin of Variation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">df</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F Crit</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positives (n = 28)</td><td align="center" valign="middle" rowspan="1" colspan="1">Between groups</td><td align="center" valign="middle" rowspan="1" colspan="1">8.495</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">4.247</td><td align="center" valign="middle" rowspan="1" colspan="1">25.611</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3.109</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">In groups</td><td align="center" valign="middle" rowspan="1" colspan="1">13.434</td><td align="center" valign="middle" rowspan="1" colspan="1">81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.166</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" rowspan="1" colspan="1">21.929</td><td align="center" valign="middle" rowspan="1" colspan="1">83</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Negatives (n = 75)</td><td align="center" valign="middle" rowspan="1" colspan="1">Between groups</td><td align="center" valign="middle" rowspan="1" colspan="1">0.871</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.435</td><td align="center" valign="middle" rowspan="1" colspan="1">19.919</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 &#x000d7; 10<sup>&#x02212;8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3.036</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">In groups</td><td align="center" valign="middle" rowspan="1" colspan="1">4.853</td><td align="center" valign="middle" rowspan="1" colspan="1">222</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.724</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">224</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t008"><object-id pub-id-type="pii">vetsci-12-00089-t008_Table 8</object-id><label>Table 8</label><caption><p>Comparison of FIVCHECK Ab ELISA (Agrolabo) with INgezim FIV ELISA (GSD) and VetLine FIV (NovaTec). Total number of samples analyzed: 103; (a) true positives; (b) false positives; (c) false negatives; (d) true negatives. Comparison results of FIVCHECK Ab ELISA and INgezim FIV ELISA: proportion of agreement (a + d/a + b + c + d) of 100% and Cohen&#x02019;s Kappa of 1.000. Comparison results of FIVCHECK Ab ELISA and VetLine FIV: proportion of agreement (a + d/a + b + c + d): 92.2%; Cohen&#x02019;s Kappa: 0.812. GSD: Gold Standard Diagnostics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Assay</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">FIVCHECK Ab ELISA (Agrolabo)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">INgezim FIV ELISA (GSD)</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (a)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (b)</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (c)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (d)</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">103</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VetLine FIV (NovaTec)</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (a)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (b)</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (c)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (d)</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t009"><object-id pub-id-type="pii">vetsci-12-00089-t009_Table 9</object-id><label>Table 9</label><caption><p>Comparative study and statistical analysis. Statistical difference was assessed by <italic toggle="yes">t</italic>-test (<italic toggle="yes">p</italic>-value &#x0003c; 0.05) and Cohen&#x02019;s d on FIVCHECK Ab ELISA (Agrolabo), INgezim FIV (Gold Standard Diagnostics, GSD) and VetLine FIV (NovaTec). Cohen&#x02019;s d (Effect size): d = 0.2 small effect, d = 0.5 moderate effect, d = 0.8 great effect.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Positive Samples</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Negative Samples</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">ELISA (Agrolabo)</th><th align="center" valign="middle" rowspan="1" colspan="1">INgezim FIV</th><th align="center" valign="middle" rowspan="1" colspan="1">VetLine FIV</th><th align="center" valign="middle" rowspan="1" colspan="1">ELISA (Agrolabo)</th><th align="center" valign="middle" rowspan="1" colspan="1">INgezim FIV </th><th align="center" valign="middle" rowspan="1" colspan="1">VetLine FIV</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">N. Tests</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">28/28</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">28/28</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">32/28</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">75/75</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">75/75</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">71/75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean OD</td><td align="center" valign="middle" rowspan="1" colspan="1">1.329</td><td align="center" valign="middle" rowspan="1" colspan="1">2.020</td><td align="center" valign="middle" rowspan="1" colspan="1">1.985</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td><td align="center" valign="middle" rowspan="1" colspan="1">0.080</td><td align="center" valign="middle" rowspan="1" colspan="1">0.204</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-value (&#x0003c;0.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2.3 &#x000d7; 10<sup>&#x02212;7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0.081</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7 &#x000d7; 10<sup>&#x02212;6</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohen&#x02019;s d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.956</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.662</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.781</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t010"><object-id pub-id-type="pii">vetsci-12-00089-t010_Table 10</object-id><label>Table 10</label><caption><p>Accelerated stability study. Analysis times: T<sub>0</sub>&#x02013;T<sub>6</sub>. OD: mean of spectrophotometric readings; %RA: percentage remaining activities; PC1: positive control anti-His HRP antibody 1:300 or 1:8000; PC2: positive control anti-His HRP antibody 1:60,000; NC: negative control; negative samples: 1, 6; positive samples: 11, 12, 3.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">Samples</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>0</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>1</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>2</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>3</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>4</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>5</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">T<sub>6</sub></th></tr><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">%RA</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">PC1 1:300</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.682</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.679</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">99.91</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.654</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.97</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.648</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.75</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.631</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.10</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.611</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">97.35</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.586</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">96.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC1 1:8000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.241</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.030</td><td align="center" valign="middle" rowspan="1" colspan="1">90.56</td><td align="center" valign="middle" rowspan="1" colspan="1">1.981</td><td align="center" valign="middle" rowspan="1" colspan="1">88.38</td><td align="center" valign="middle" rowspan="1" colspan="1">1.881</td><td align="center" valign="middle" rowspan="1" colspan="1">83.91</td><td align="center" valign="middle" rowspan="1" colspan="1">1.843</td><td align="center" valign="middle" rowspan="1" colspan="1">82.22</td><td align="center" valign="middle" rowspan="1" colspan="1">1.849</td><td align="center" valign="middle" rowspan="1" colspan="1">82.49</td><td align="center" valign="middle" rowspan="1" colspan="1">1.717</td><td align="center" valign="middle" rowspan="1" colspan="1">76.59</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC2 1:60,000</td><td align="center" valign="middle" rowspan="1" colspan="1">3.138</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">3.128</td><td align="center" valign="middle" rowspan="1" colspan="1">99.70</td><td align="center" valign="middle" rowspan="1" colspan="1">3.039</td><td align="center" valign="middle" rowspan="1" colspan="1">96.86</td><td align="center" valign="middle" rowspan="1" colspan="1">2.939</td><td align="center" valign="middle" rowspan="1" colspan="1">93.66</td><td align="center" valign="middle" rowspan="1" colspan="1">2.823</td><td align="center" valign="middle" rowspan="1" colspan="1">89.96</td><td align="center" valign="middle" rowspan="1" colspan="1">2.461</td><td align="center" valign="middle" rowspan="1" colspan="1">78.44</td><td align="center" valign="middle" rowspan="1" colspan="1">2.246</td><td align="center" valign="middle" rowspan="1" colspan="1">71.59</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">94.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">94.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">92.54</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">86.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">89.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">83.58</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 1 (&#x02212;)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">92.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047</td><td align="center" valign="middle" rowspan="1" colspan="1">89.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">86.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">79.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">75.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">69.52</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 6 (&#x02212;)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">95.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">91.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">82.93</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">80.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">90.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">75.61</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 11 (+)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.708</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">1.715</td><td align="center" valign="middle" rowspan="1" colspan="1">100.41</td><td align="center" valign="middle" rowspan="1" colspan="1">1.538</td><td align="center" valign="middle" rowspan="1" colspan="1">90.02</td><td align="center" valign="middle" rowspan="1" colspan="1">1.517</td><td align="center" valign="middle" rowspan="1" colspan="1">88.82</td><td align="center" valign="middle" rowspan="1" colspan="1">1.295</td><td align="center" valign="middle" rowspan="1" colspan="1">75.82</td><td align="center" valign="middle" rowspan="1" colspan="1">1.242</td><td align="center" valign="middle" rowspan="1" colspan="1">72.69</td><td align="center" valign="middle" rowspan="1" colspan="1">1.210</td><td align="center" valign="middle" rowspan="1" colspan="1">70.84</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 12 (+)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.478</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">1.492</td><td align="center" valign="middle" rowspan="1" colspan="1">100.98</td><td align="center" valign="middle" rowspan="1" colspan="1">1.354</td><td align="center" valign="middle" rowspan="1" colspan="1">91.64</td><td align="center" valign="middle" rowspan="1" colspan="1">1.185</td><td align="center" valign="middle" rowspan="1" colspan="1">80.20</td><td align="center" valign="middle" rowspan="1" colspan="1">1.156</td><td align="center" valign="middle" rowspan="1" colspan="1">78.24</td><td align="center" valign="middle" rowspan="1" colspan="1">1.083</td><td align="center" valign="middle" rowspan="1" colspan="1">73.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1.029</td><td align="center" valign="middle" rowspan="1" colspan="1">69.61</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sample 3 (+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.369</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.375</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.370</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.234</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.180</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.999</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.00</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00089-t011"><object-id pub-id-type="pii">vetsci-12-00089-t011_Table 11</object-id><label>Table 11</label><caption><p>Real-time stability study. Analysis times: T<sub>0</sub>&#x02013;T<sub>12</sub>. OD: mean of spectrophotometric readings; %RA: percentage remaining activities; PC1: positive control anti-His HRP antibody 1:300 or 1:8000; PC2: positive control anti-His HRP antibody 1:60,000; NC: negative control; negative samples: 1, 6; positive samples: 11, 12, 3.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Samples</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>0</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>1</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>2</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>3</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>4</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>5</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>6</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>7</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>8</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>9</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>10</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>11</sub></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>12</sub></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th><th align="center" valign="middle" rowspan="1" colspan="1">OD</th><th align="center" valign="middle" rowspan="1" colspan="1">%RA</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">PC1 1:300</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.682</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.690</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">100.30</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.636</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.30</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.634</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.21</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.629</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.04</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.631</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.12</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.650</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.83</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.640</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.45</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.664</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">99.33</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.623</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">97.82</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.632</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">98.15</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.498</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">93.15</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2.387</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">89.00</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC1 1:8000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.241</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.243</td><td align="center" valign="middle" rowspan="1" colspan="1">100.07</td><td align="center" valign="middle" rowspan="1" colspan="1">2.245</td><td align="center" valign="middle" rowspan="1" colspan="1">100.16</td><td align="center" valign="middle" rowspan="1" colspan="1">2.243</td><td align="center" valign="middle" rowspan="1" colspan="1">100.09</td><td align="center" valign="middle" rowspan="1" colspan="1">2.242</td><td align="center" valign="middle" rowspan="1" colspan="1">100.02</td><td align="center" valign="middle" rowspan="1" colspan="1">2.246</td><td align="center" valign="middle" rowspan="1" colspan="1">100.20</td><td align="center" valign="middle" rowspan="1" colspan="1">2.241</td><td align="center" valign="middle" rowspan="1" colspan="1">100.00</td><td align="center" valign="middle" rowspan="1" colspan="1">2.363</td><td align="center" valign="middle" rowspan="1" colspan="1">105.42</td><td align="center" valign="middle" rowspan="1" colspan="1">2.240</td><td align="center" valign="middle" rowspan="1" colspan="1">99.93</td><td align="center" valign="middle" rowspan="1" colspan="1">1.903</td><td align="center" valign="middle" rowspan="1" colspan="1">84.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.924</td><td align="center" valign="middle" rowspan="1" colspan="1">85.83</td><td align="center" valign="middle" rowspan="1" colspan="1">1.881</td><td align="center" valign="middle" rowspan="1" colspan="1">83.91</td><td align="center" valign="middle" rowspan="1" colspan="1">1.637</td><td align="center" valign="middle" rowspan="1" colspan="1">73.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC2 1:60,000</td><td align="center" valign="middle" rowspan="1" colspan="1">3.138</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">3.132</td><td align="center" valign="middle" rowspan="1" colspan="1">99.81</td><td align="center" valign="middle" rowspan="1" colspan="1">3.123</td><td align="center" valign="middle" rowspan="1" colspan="1">99.54</td><td align="center" valign="middle" rowspan="1" colspan="1">3.124</td><td align="center" valign="middle" rowspan="1" colspan="1">99.55</td><td align="center" valign="middle" rowspan="1" colspan="1">3.166</td><td align="center" valign="middle" rowspan="1" colspan="1">100.89</td><td align="center" valign="middle" rowspan="1" colspan="1">2.923</td><td align="center" valign="middle" rowspan="1" colspan="1">93.15</td><td align="center" valign="middle" rowspan="1" colspan="1">2.867</td><td align="center" valign="middle" rowspan="1" colspan="1">91.38</td><td align="center" valign="middle" rowspan="1" colspan="1">2.870</td><td align="center" valign="middle" rowspan="1" colspan="1">91.46</td><td align="center" valign="middle" rowspan="1" colspan="1">2.710</td><td align="center" valign="middle" rowspan="1" colspan="1">86.36</td><td align="center" valign="middle" rowspan="1" colspan="1">2.697</td><td align="center" valign="middle" rowspan="1" colspan="1">85.94</td><td align="center" valign="middle" rowspan="1" colspan="1">2.602</td><td align="center" valign="middle" rowspan="1" colspan="1">82.93</td><td align="center" valign="middle" rowspan="1" colspan="1">2.467</td><td align="center" valign="middle" rowspan="1" colspan="1">78.63</td><td align="center" valign="middle" rowspan="1" colspan="1">2.364</td><td align="center" valign="middle" rowspan="1" colspan="1">75.35</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">86.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">91.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">88.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">86.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">88.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">83.58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">88.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">86.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">88.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" rowspan="1" colspan="1">89.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">88.00</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">90.48</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">85.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">84.76</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">86.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">81.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">87.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">84.76</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">80.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">76.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">85.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">80.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">77.47</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 6 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">93.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">93.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">93.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">85.37</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">81.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">86.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">91.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">104.88</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">103.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">108.54</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">93.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">87.49</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 11</td><td align="center" valign="middle" rowspan="1" colspan="1">2.708</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.866</td><td align="center" valign="middle" rowspan="1" colspan="1">105.84</td><td align="center" valign="middle" rowspan="1" colspan="1">2.866</td><td align="center" valign="middle" rowspan="1" colspan="1">105.83</td><td align="center" valign="middle" rowspan="1" colspan="1">2.864</td><td align="center" valign="middle" rowspan="1" colspan="1">105.76</td><td align="center" valign="middle" rowspan="1" colspan="1">2.845</td><td align="center" valign="middle" rowspan="1" colspan="1">105.06</td><td align="center" valign="middle" rowspan="1" colspan="1">2.861</td><td align="center" valign="middle" rowspan="1" colspan="1">105.65</td><td align="center" valign="middle" rowspan="1" colspan="1">2.863</td><td align="center" valign="middle" rowspan="1" colspan="1">105.71</td><td align="center" valign="middle" rowspan="1" colspan="1">2.865</td><td align="center" valign="middle" rowspan="1" colspan="1">105.78</td><td align="center" valign="middle" rowspan="1" colspan="1">2.531</td><td align="center" valign="middle" rowspan="1" colspan="1">93.45</td><td align="center" valign="middle" rowspan="1" colspan="1">2.169</td><td align="center" valign="middle" rowspan="1" colspan="1">80.10</td><td align="center" valign="middle" rowspan="1" colspan="1">2.241</td><td align="center" valign="middle" rowspan="1" colspan="1">82.74</td><td align="center" valign="middle" rowspan="1" colspan="1">2.199</td><td align="center" valign="middle" rowspan="1" colspan="1">81.20</td><td align="center" valign="middle" rowspan="1" colspan="1">2.045</td><td align="center" valign="middle" rowspan="1" colspan="1">75.51</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sample 12</td><td align="center" valign="middle" rowspan="1" colspan="1">2.478</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.684</td><td align="center" valign="middle" rowspan="1" colspan="1">108.34</td><td align="center" valign="middle" rowspan="1" colspan="1">2.635</td><td align="center" valign="middle" rowspan="1" colspan="1">106.36</td><td align="center" valign="middle" rowspan="1" colspan="1">2.632</td><td align="center" valign="middle" rowspan="1" colspan="1">106.24</td><td align="center" valign="middle" rowspan="1" colspan="1">2.634</td><td align="center" valign="middle" rowspan="1" colspan="1">106.30</td><td align="center" valign="middle" rowspan="1" colspan="1">2.646</td><td align="center" valign="middle" rowspan="1" colspan="1">106.78</td><td align="center" valign="middle" rowspan="1" colspan="1">2.648</td><td align="center" valign="middle" rowspan="1" colspan="1">106.86</td><td align="center" valign="middle" rowspan="1" colspan="1">2.642</td><td align="center" valign="middle" rowspan="1" colspan="1">106.64</td><td align="center" valign="middle" rowspan="1" colspan="1">2.512</td><td align="center" valign="middle" rowspan="1" colspan="1">101.37</td><td align="center" valign="middle" rowspan="1" colspan="1">2.047</td><td align="center" valign="middle" rowspan="1" colspan="1">82.62</td><td align="center" valign="middle" rowspan="1" colspan="1">1.849</td><td align="center" valign="middle" rowspan="1" colspan="1">74.63</td><td align="center" valign="middle" rowspan="1" colspan="1">1.841</td><td align="center" valign="middle" rowspan="1" colspan="1">74.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1.734</td><td align="center" valign="middle" rowspan="1" colspan="1">70.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sample 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.369</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.476</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.469</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.465</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.470</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.475</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.477</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.476</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.541</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.082</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.867</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.806</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.730</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.02</td></tr></tbody></table></table-wrap></floats-group></article>